

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Managing portal hypertension in patients with liver... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-533/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-533" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Managing portal hypertension in patients with liver cirrhosis" />
    
            <meta name="og:title" content="F1000Research Article: Managing portal hypertension in patients with liver cirrhosis.">
            <meta name="og:description" content="Read the latest article version by Tilman Sauerbruch, Robert Schierwagen, Jonel Trebicka, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="15157">
            <meta name="article-id" content="13943">
            <meta name="dc.title" content="Managing portal hypertension in patients with liver cirrhosis">
            <meta name="dc.description" content="Portal hypertension is one cause and a part of a dynamic process triggered by chronic liver disease, mostly induced by alcohol or incorrect nutrition and less often by viral infections and autoimmune or genetic disease. Adequate staging - continuously modified by current knowledge - should guide the prevention and treatment of portal hypertension with defined endpoints. The main goals are interruption of etiology and prevention of complications followed, if necessary, by treatment of these. For the past few decades, shunts, mostly as intrahepatic stent bypass between portal and hepatic vein branches, have played an important role in the prevention of recurrent bleeding and ascites formation, although their impact on survival remains ambiguous. Systemic drugs, such as non-selective beta-blockers, statins, or antibiotics, reduce portal hypertension by decreasing intrahepatic resistance or portal tributary blood flow or by blunting inflammatory stimuli inside and outside the liver. Here, the interactions among the gut, liver, and brain are increasingly examined for new therapeutic options. There is no general panacea. The interruption of initiating factors is key. If not possible or if not possible in a timely manner, combined approaches should receive more attention before considering liver transplantation.">
            <meta name="dc.subject" content="portal hypertension, liver cirrhosis, chronic liver disease">
            <meta name="dc.creator" content="Sauerbruch, Tilman">
            <meta name="dc.creator" content="Schierwagen, Robert">
            <meta name="dc.creator" content="Trebicka, Jonel">
            <meta name="dc.date" content="2018/05/02">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.13943.1">
            <meta name="dc.source" content="F1000Research 2018 7:533">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="portal hypertension">
            <meta name="prism.keyword" content="liver cirrhosis">
            <meta name="prism.keyword" content="chronic liver disease">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/05/02">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="533">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.13943.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-533">
            <meta name="citation_title" content="Managing portal hypertension in patients with liver cirrhosis">
            <meta name="citation_abstract" content="Portal hypertension is one cause and a part of a dynamic process triggered by chronic liver disease, mostly induced by alcohol or incorrect nutrition and less often by viral infections and autoimmune or genetic disease. Adequate staging - continuously modified by current knowledge - should guide the prevention and treatment of portal hypertension with defined endpoints. The main goals are interruption of etiology and prevention of complications followed, if necessary, by treatment of these. For the past few decades, shunts, mostly as intrahepatic stent bypass between portal and hepatic vein branches, have played an important role in the prevention of recurrent bleeding and ascites formation, although their impact on survival remains ambiguous. Systemic drugs, such as non-selective beta-blockers, statins, or antibiotics, reduce portal hypertension by decreasing intrahepatic resistance or portal tributary blood flow or by blunting inflammatory stimuli inside and outside the liver. Here, the interactions among the gut, liver, and brain are increasingly examined for new therapeutic options. There is no general panacea. The interruption of initiating factors is key. If not possible or if not possible in a timely manner, combined approaches should receive more attention before considering liver transplantation.">
            <meta name="citation_description" content="Portal hypertension is one cause and a part of a dynamic process triggered by chronic liver disease, mostly induced by alcohol or incorrect nutrition and less often by viral infections and autoimmune or genetic disease. Adequate staging - continuously modified by current knowledge - should guide the prevention and treatment of portal hypertension with defined endpoints. The main goals are interruption of etiology and prevention of complications followed, if necessary, by treatment of these. For the past few decades, shunts, mostly as intrahepatic stent bypass between portal and hepatic vein branches, have played an important role in the prevention of recurrent bleeding and ascites formation, although their impact on survival remains ambiguous. Systemic drugs, such as non-selective beta-blockers, statins, or antibiotics, reduce portal hypertension by decreasing intrahepatic resistance or portal tributary blood flow or by blunting inflammatory stimuli inside and outside the liver. Here, the interactions among the gut, liver, and brain are increasingly examined for new therapeutic options. There is no general panacea. The interruption of initiating factors is key. If not possible or if not possible in a timely manner, combined approaches should receive more attention before considering liver transplantation.">
            <meta name="citation_keywords" content="portal hypertension, liver cirrhosis, chronic liver disease">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Tilman Sauerbruch">
            <meta name="citation_author_institution" content="Department of Internal Medicine, University of Bonn, Bonn, Germany">
            <meta name="citation_author" content="Robert Schierwagen">
            <meta name="citation_author_institution" content="Department of Internal Medicine, University of Bonn, Bonn, Germany">
            <meta name="citation_author" content="Jonel Trebicka">
            <meta name="citation_author_institution" content="Department of Internal Medicine, University of Bonn, Bonn, Germany">
            <meta name="citation_author_institution" content="European Foundation for Study of Chronic Liver Failure, Barcelona, Spain">
            <meta name="citation_publication_date" content="2018/05/02">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="533">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.13943.1">
            <meta name="citation_firstpage" content="533">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-533/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-533.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=15157 /> <input type=hidden id=articleId name=articleId value=13943 /> <input type=hidden id=xmlUrl value="/articles/7-533/v1/xml"/> <input type=hidden id=xmlFileName value="-7-533-v1.xml"> <input type=hidden id=article_uuid value=440d6d98-e9fa-45cc-b787-9b59b64fc85a /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Managing portal hypertension in patients with liver cirrhosis"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.13943.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.13943.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-533"
  },
  "headline": "Managing portal hypertension in patients with liver cirrhosis",
  "datePublished": "2018-05-02T16:26:18",
  "dateModified": "2018-05-02T16:26:18",
  "author": [
    {
      "@type": "Person",
      "name": "Tilman Sauerbruch"
    },    {
      "@type": "Person",
      "name": "Robert Schierwagen"
    },    {
      "@type": "Person",
      "name": "Jonel Trebicka"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Portal hypertension is one cause and a part of a dynamic process triggered by chronic liver disease, mostly induced by alcohol or incorrect nutrition and less often by viral infections and autoimmune or genetic disease. Adequate staging - continuously modified by current knowledge - should guide the prevention and treatment of portal hypertension with defined endpoints. The main goals are interruption of etiology and prevention of complications followed, if necessary, by treatment of these. For the past few decades, shunts, mostly as intrahepatic stent bypass between portal and hepatic vein branches, have played an important role in the prevention of recurrent bleeding and ascites formation, although their impact on survival remains ambiguous. Systemic drugs, such as non-selective beta-blockers, statins, or antibiotics, reduce portal hypertension by decreasing intrahepatic resistance or portal tributary blood flow or by blunting inflammatory stimuli inside and outside the liver. Here, the interactions among the gut, liver, and brain are increasingly examined for new therapeutic options. There is no general panacea. The interruption of initiating factors is key. If not possible or if not possible in a timely manner, combined approaches should receive more attention before considering liver transplantation."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-533/v1",
            "name": "Managing portal hypertension in patients with liver cirrhosis"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Managing portal hypertension in patients with liver cirrhosis </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=15157 data-id=13943 data-downloads="" data-views="" data-scholar="10.12688/f1000research.13943.1" data-recommended="" data-doi="10.12688/f1000research.13943.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-533/v1/pdf?article_uuid=440d6d98-e9fa-45cc-b787-9b59b64fc85a" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-13943-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-13943-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-13943-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Sauerbruch T, Schierwagen R and Trebicka J. Managing portal hypertension in patients with liver cirrhosis [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):533 (<a class=new-orange href="https://doi.org/10.12688/f1000research.13943.1" target=_blank>https://doi.org/10.12688/f1000research.13943.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-13943-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=13943 id=track-article-signin-13943 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/13943?target=/articles/7-533/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15157 /> <input name=articleId type=hidden value=13943 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Managing portal hypertension in patients with liver cirrhosis</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:sauerbruch@uni-bonn.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Tilman Sauerbruch</span></a><a href="https://orcid.org/0000-0001-7636-1134" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7636-1134</div><sup>1</sup>,&nbsp;</span><span class="">Robert Schierwagen<sup>1</sup>,&nbsp;</span><span class="">Jonel Trebicka<sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:sauerbruch@uni-bonn.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Tilman Sauerbruch</span></a><a href="http://orcid.org/0000-0001-7636-1134" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7636-1134</div><sup>1</sup>,&nbsp;</span><span class="">Robert Schierwagen<sup>1</sup>,&nbsp;</span><span class="">Jonel Trebicka<sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 02 May 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.13943.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Internal Medicine, University of Bonn, Bonn, Germany<br/> <sup>2</sup> European Foundation for Study of Chronic Liver Failure, Barcelona, Spain<br/> <p> <div class=margin-bottom> Tilman Sauerbruch <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Robert Schierwagen <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Jonel Trebicka <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=33967-33469></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=10304-33470></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Portal hypertension is one cause and a part of a dynamic process triggered by chronic liver disease, mostly induced by alcohol or incorrect nutrition and less often by viral infections and autoimmune or genetic disease. Adequate staging - continuously modified by current knowledge - should guide the prevention and treatment of portal hypertension with defined endpoints. The main goals are interruption of etiology and prevention of complications followed, if necessary, by treatment of these. For the past few decades, shunts, mostly as intrahepatic stent bypass between portal and hepatic vein branches, have played an important role in the prevention of recurrent bleeding and ascites formation, although their impact on survival remains ambiguous. Systemic drugs, such as non-selective beta-blockers, statins, or antibiotics, reduce portal hypertension by decreasing intrahepatic resistance or portal tributary blood flow or by blunting inflammatory stimuli inside and outside the liver. Here, the interactions among the gut, liver, and brain are increasingly examined for new therapeutic options. There is no general panacea. The interruption of initiating factors is key. If not possible or if not possible in a timely manner, combined approaches should receive more attention before considering liver transplantation. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> portal hypertension, liver cirrhosis, chronic liver disease </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Tilman Sauerbruch (<a href="mailto:sauerbruch@uni-bonn.de">sauerbruch@uni-bonn.de</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Tilman Sauerbruch </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by Deutsche Forschungsgemeinschaft (SFB TRR57), the Cellex Foundation, and the European Union’s Horizon 2020 research and innovation program (No 668031). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Sauerbruch T <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Sauerbruch T, Schierwagen R and Trebicka J. Managing portal hypertension in patients with liver cirrhosis [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):533 (<a href="https://doi.org/10.12688/f1000research.13943.1" target=_blank>https://doi.org/10.12688/f1000research.13943.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 02 May 2018, <b>7</b>(F1000 Faculty Rev):533 (<a href="https://doi.org/10.12688/f1000research.13943.1" target=_blank>https://doi.org/10.12688/f1000research.13943.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 02 May 2018, <b>7</b>(F1000 Faculty Rev):533 (<a href="https://doi.org/10.12688/f1000research.13943.1" target=_blank>https://doi.org/10.12688/f1000research.13943.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d95755e185>Introduction</h2><p class="" id=d95755e188>Portal hypertension is defined as the pathological increase of portal venous pressure, mainly due to chronic end-stage liver disease, leading to augmented hepatic vascular resistance and congestion of the blood in the portal venous system. This pathology may result in a series of complications, such as the formation of collateral vessels for return of the blood to the right atrium with potential for intestinal bleeding, formation of ascites, encephalopathy, and development of a hyperdynamic circulation involving peripheral and splanchnic vessels<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup> associated with dysfunction of the kidneys<sup><a href="#ref-3">3</a></sup>, the heart<sup><a href="#ref-4">4</a></sup>, the lungs<sup><a href="#ref-5">5</a></sup>, and the brain<sup><a href="#ref-6">6</a></sup> (<a href="#f1">Figure 1</a> and <a href="#f2">Figure 2</a>). A complex interplay among inflammatory stimuli, vasoregulatory molecules, neurotransmitters, and ion channels maintains and drives these processes. Thus, portal hypertension is one cause and a part of a dynamic process triggered by chronic liver disease and systemic inflammation<sup><a href="#ref-7">7</a></sup>. In the stage of advanced liver disease, mostly fixed structural changes, such as fibrosis or the formation of regenerative nodules, are responsible for developing and sustaining portal hypertension. In addition, dynamic components involving the regulation of blood flow in different vascular beds play a decisive role in the modulation of portal pressure and its associated pathophysiology. Systemic therapy is aimed at the modulation of these dynamic parts. Most likely, they are more or less similar in end-stage liver disease, regardless of the etiology of hepatic damage. However, in the early stages of liver disease, the pathological chain of events depends more on the causative factors, be they metabolic, infectious, or autoimmune. Thus, early and specific treatment is the foremost aim. During later stages of liver disease, distinct treatment of the initiating factors may still be pivotal, i.e. interruption of viremia or alcohol abuse (<a href="#f1">Figure 1</a> and <a href="#f2">Figure 2</a>). However, this must be combined with measures to prevent or treat complications due to liver cirrhosis.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/15157/5ab87871-1f81-40ae-9097-1f04b7faa1fe_figure1.gif"><img alt="5ab87871-1f81-40ae-9097-1f04b7faa1fe_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/15157/5ab87871-1f81-40ae-9097-1f04b7faa1fe_figure1.gif"></a><div class=caption><h3>Figure 1. Two main pathways in the development of liver disease.</h3><p id=d95755e241> <b>A</b>. The liver (L) is primarily affected (mainly by chronic infection with hepatotropic viruses). This leads to liver cirrhosis and portal hypertension causing leakiness of the intestine (I) and dysbiosis, affecting the brain (<b>B</b>), and altering the splanchnic and systemic circulation, including the heart (H) and the kidneys (K). Prevention and therapy is interruption and/or suppression of viremia. <b>B</b>. Increasingly, nutrition has become the main culprit in liver disease. Here, inflammatory and metabolic stimuli from the gut affect the liver, visceral fat (VF), and cardiovascular system, including the heart and the kidneys, but also, concomitantly and early on in the process, the brain, which may support a vicious cycle of craving more food and liquids. Prevention and therapy is modification of food and liquid intake. Only in the later stages of liver disease do the complications of liver cirrhosis and portal hypertension determine pathogenesis, diagnosis, and therapy similar to <b>A</b>).</p></div></div><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/15157/5ab87871-1f81-40ae-9097-1f04b7faa1fe_figure2.gif"><img alt="5ab87871-1f81-40ae-9097-1f04b7faa1fe_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/15157/5ab87871-1f81-40ae-9097-1f04b7faa1fe_figure2.gif"></a><div class=caption><h3>Figure 2. Stages of chronic liver disease and portal hypertension.</h3><p id=d95755e270>The figure depicts the diagnostic and therapeutic procedures during the pathogenesis and aggravation of portal hypertension for patients with suspected fibrosis/cirrhosis of the liver (<b>A</b>), compensated cirrhosis (<b>B</b>), and decompensated cirrhosis (<b>C</b>). Asc, ascites; EV, esophageal varices; FXR, farnesoid X receptor; HCC, hepatocellular carcinoma; HVPG, hepatic venous pressure gradient; IB, intestinal barrier; IH, intrahepatic; IHR, intrahepatic resistance; M, microbiome; MRI, magnet resonance imaging; NSBB, non-selective beta-blocker; SVB, splanchnic vascular bed; US, ultrasound.</p></div></div><p class="" id=d95755e286>This review focuses on portal hypertension in patients with advanced liver disease. It will address some open questions and new approaches on how to stage chronic liver disease and portal hypertension and how to prevent some of its complications.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d95755e292>Staging of chronic liver disease and portal hypertension</h2><p class="" id=d95755e295>For staging of chronic liver disease, a variety of different tools are available, including physical examination, laboratory tests, imaging techniques, and hemodynamic measurements (<a href="#f2">Figure 2</a>). Imaging techniques comprise endoscopy, ultrasound, determination of liver stiffness, computed tomography, and magnetic resonance imaging (MRI). Physical examination includes important parameters of the Child–Pugh classification<sup><a href="#ref-8">8</a></sup>. If there are no signs of jaundice, ascites, or encephalopathy, the patient has a good chance of being in a compensated stage of cirrhosis with a 10-year survival of above 50%, while clinical signs of decompensation indicate a mortality of more than 75% within the next 5 years<sup><a href="#ref-9">9</a></sup>.</p><p class="" id=d95755e309>Endoscopy is still the best method to assess the existence of varices in the upper intestinal tract as well as their size and potential to bleed or rebleed<sup><a href="#ref-10">10</a></sup>. While in any patient with suspected liver cirrhosis a standard examination used to include endoscopy, new guidelines recommend abstaining from early endoscopy in patients with liver stiffness &lt;20 kPa and platelet count &gt;150 G/L<sup><a href="#ref-11">11</a>,<a href="#ref-12">12</a></sup>. These patients have a high probability of being free of esophageal varices<sup><a href="#ref-13">13</a></sup>. However, endoscopy retains its central role as the entrance test for the initiation of primary and secondary prophylaxis of variceal bleeding in patients with higher stiffness values or a lower platelet count, and it is still the central method for the assessment of variceal bleeding and hemostasis<sup><a href="#ref-12">12</a></sup>.</p><p class="" id=d95755e331>In addition, elastographic techniques enable estimation of the degree of liver fibrosis via transient elastography (TE), acoustic radiation force impulse imaging (ARFI), or shear wave elastography (SWE)<sup><a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup>. Determination of liver stiffness has by now become an important tool for screening of fibrosis and portal hypertension in patients with liver disease. Fibrosis leads to an increased stiffness of the liver. In organs with higher stiffness, shear waves travel with a higher speed through tissues. By delivering pulses, shear waves can be induced to assess their speed as an indirect measure of fibrosis. There are different systems using mechanical 50 Hz pulses (TE), a focused ultrasound pulse to deform internal tissue (AFRI and SWE), or a two-dimensional gradient-recalled-echo sequence analyzed by certain algorithms (magnetic resonance [MR] elastography).</p><p class="" id=d95755e341>The most extensive experience to date exists for TE, a stand-alone technique based on shear wave speed measurement, not integrated into ultrasound devices<sup><a href="#ref-16">16</a>–<a href="#ref-18">18</a></sup>. Values below 5.2–9.5 kPa (TE) or 1.22–1.63 m/s (ARFI) can rule out significant liver fibrosis, whereas higher values may be falsely positive with respect to cirrhosis assessment because of obstructive cholestasis, liver congestion, severe liver inflammation, or infiltrative liver disease<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. However, many of these obscuring conditions can be assessed or ruled out by using ultrasound-based techniques such as SWE or AFRI. SWE has shown slightly better sensitivity and specificity for liver fibrosis and portal hypertension when compared to TE<sup><a href="#ref-19">19</a></sup>. Nevertheless, observing standardized conditions like fasting state is important<sup><a href="#ref-20">20</a></sup>. By combining liver and spleen SWE, portal hypertension can be excluded with a very high probability<sup><a href="#ref-21">21</a></sup> on the one hand or assessed in its clinically significant form on the other<sup><a href="#ref-22">22</a></sup>. Furthermore, ultrasound-based techniques allow for hepatocellular carcinoma (HCC) screening.</p><p class="" id=d95755e376>The different systems have pros and cons. TE is available in many centers and is excellently validated but may have a high failure rate in obese patients or in patients with ascites. AFRI allows ultrasound guidance for the region of interest but is less validated, and high body weight may also be a problem. MR elastography allows one to cover a large sampling volume, but it is affected by iron deposition, high body mass index, and massive ascites<sup><a href="#ref-23">23</a></sup>.</p><p class="" id=d95755e383>Ultrasound allows a more sensitive and specific assessment of ascites than clinical examination together with assessment of size, surface, and echotexture of the liver.</p><p class="" id=d95755e386>Similar to ultrasound, computed tomography and MRI are relevant for the diagnosis of HCC. This is important, since liver fibrosis or cirrhosis is a precancerous condition. Of all imaging devices, MRI has the broadest potential for staging liver disease with respect to morphology, including the biliary system, tissue texture, perfusion, formation of collaterals, function of hepatic cells<sup><a href="#ref-24">24</a>–<a href="#ref-26">26</a></sup>, and quantification of steatosis or fibrosis<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. However, it is expensive and not always available. We recently showed how MRI can be used to measure fat-free muscle area as a prognostic marker of sarcopenia, correlated with survival<sup><a href="#ref-29">29</a></sup> in patients with liver cirrhosis.</p><p class="" id=d95755e407>Among hemodynamic measurements, assessment of the hepatic venous pressure gradient (HVPG)<sup><a href="#ref-30">30</a></sup> is the most important in chronic liver disease. Developed in the 1950s<sup><a href="#ref-31">31</a></sup> and later modified by Groszmann <i>et al</i>.<sup><a href="#ref-32">32</a></sup>, it has become the gold standard for indirect assessment of the degree of portal hypertension. The HVPG value closely correlates with the portal vein pressure, especially in alcoholic liver disease<sup><a href="#ref-33">33</a></sup>, which in turn shows a significant correlation with blood pressure in esophageal varices<sup><a href="#ref-34">34</a></sup>. HVPG values above 5 mmHg are regarded as portal hypertension. Measurement of the HVPG adds prognostic information to standard laboratory and clinical evaluations in advanced liver disease<sup><a href="#ref-35">35</a>,<a href="#ref-36">36</a></sup>. Patients with compensated cirrhosis and HVPG &lt;10 mmHg have a rather low risk of developing varices or decompensation of liver function<sup><a href="#ref-37">37</a></sup>. It is generally accepted that esophageal varices do not bleed if HVPG remains below 12 mmHg and that a reduction of HVPG by more than 20%, regardless of the baseline value, considerably reduces the risk of bleeding from varices. Thus, measurement of HVPG has repeatedly been advocated as a means to tailor the treatment for variceal bleeding<sup><a href="#ref-35">35</a>,<a href="#ref-38">38</a></sup>. There is a good correlation between liver stiffness, as assessed by TE, and HVPG<sup><a href="#ref-39">39</a></sup>. Values below 14 kPa exclude clinically significant portal hypertension (HVPG ≥10 mmHg) with high sensitivity and specificity<sup><a href="#ref-40">40</a></sup>.</p><p class="" id=d95755e460>Since the introduction of the Child–Turcotte classification<sup><a href="#ref-8">8</a></sup> and its modification according to Pugh <i>et al</i>.<sup><a href="#ref-41">41</a></sup>, it has been repeatedly shown that, in patients with liver cirrhosis, laboratory values reflecting hepatocyte function, e.g. uptake and secretion of bilirubin or synthesis of proteins, allow prediction of the probability of survival. Thus, serum levels of bilirubin, albumin, or clotting factors have been used for decades to stage chronic liver disease. They are part of the model for end-stage liver disease (MELD) system<sup><a href="#ref-42">42</a></sup> as well as of the Child–Pugh classification<sup><a href="#ref-41">41</a></sup>.</p><p class="" id=d95755e482>The MELD consists of serum levels of bilirubin and creatinine and prothrombin time determined as an international normalized ratio (INR). Initially developed to determine the prognosis of patients receiving a transjugular intrahepatic portosystemic shunt (TIPS)<sup><a href="#ref-42">42</a>,<a href="#ref-43">43</a></sup>, it is now used to assess organ allocation priority for liver transplantation. It can be calculated easily, has been validated prospectively in different cohorts, and contains no clinical parameters based on subjective assessment. Nevertheless, MELD is only slightly superior to the Child–Pugh model in the prediction of survival<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>. The addition of further parameters such as sodium<sup><a href="#ref-46">46</a></sup>, hepatic encephalopathy<sup><a href="#ref-45">45</a></sup>, or sarcopenia<sup><a href="#ref-47">47</a></sup> to MELD has been described to further improve prognosis with marginal effects.</p><p class="" id=d95755e512>Impairment of kidney function, such as sodium handling, occurs early in patients with liver disease<sup><a href="#ref-48">48</a></sup>, and elevated creatinine levels—or, more importantly, an increase in serum creatinine by ≥0.3 mg/dL - are independent markers for negative patient outcome<sup><a href="#ref-49">49</a></sup>.</p><p class="" id=d95755e523>Patients with liver cirrhosis are prone to systemic inflammation, where mostly cytokines of the innate immune system are involved<sup><a href="#ref-50">50</a></sup>. This paves the way towards fatal dysfunction of organs, now coined acute-on-chronic liver failure (ACLF)<sup><a href="#ref-51">51</a></sup>. Thus, signs of inflammation, such as high leukocyte count and elevated C-reactive protein, are additional important prognostic parameters<sup><a href="#ref-52">52</a></sup>. Interestingly, there is a subgroup of patients who, even after TIPS insertion, show an increased or unchanged liver stiffness. These are patients with high levels of proinflammatory cytokines. They have a bad outcome<sup><a href="#ref-53">53</a></sup>. Thus, dynamics in liver stiffness may be an easy read-out to assess inflammation and prognosis in TIPS patients. Furthermore, the individual genetic background with respect to genes coding for proteins involved in the immune response may predispose patients to infections, ACLF, and decompensation<sup><a href="#ref-54">54</a>–<a href="#ref-58">58</a></sup>.</p><p class="" id=d95755e549>Many of the above-mentioned parameters are part of staging systems for liver cirrhosis designed to distinguish between compensated and decompensated disease at different states<sup><a href="#ref-59">59</a></sup>. If it is true that the intestine is important for the initiation and perpetuation of liver disease (see below), we will also need some sort of staging for intestinal dysfunction in patients with liver disease in the future.</p><p class="" id=d95755e556>The different staging systems mentioned above, such as the degree of fibrosis, HVPG, ongoing etiology, Child–Pugh, dynamics of kidney dysfunction, or signs of inflammation, are partly interrelated. Thus, HVPG increases with the degree of cirrhosis<sup><a href="#ref-60">60</a>,<a href="#ref-61">61</a></sup> or the degree of decompensation as assessed by the Child–Pugh score. However, the correlation is loose, and the prognostic value of HVPG is partly independent of the Child–Pugh system<sup><a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>. Therefore, there is always the question of how to integrate different parameters or scores into an appropriate and simple bedside system. Clinical judgment is quite accurate for advanced liver disease. Jaundice and ascites are markers of bad prognosis. In this situation, bleeding, infections, overt encephalopathy, and deterioration of kidney function denote high risk of death. Determination of HVPG and/or of liver stiffness may improve long-term prognosis in patients with compensated cirrhosis<sup><a href="#ref-59">59</a></sup>, and HVPG alone is an independent prognostic marker in patients with decompensated cirrhosis and variceal bleeding<sup><a href="#ref-36">36</a>,<a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>. In the future, we will probably have to adapt to more complex systems<sup><a href="#ref-59">59</a>,<a href="#ref-64">64</a></sup> which might improve prognosis and therapy. No matter which stage of disease, the interruption of etiology, be it alcohol intake or viremia, is crucial.</p><p class="" id=d95755e594>As with all staging systems in medicine, the question arises as to whether these surrogates or biomarkers can guide the prevention or treatment of relevant clinical endpoints in patients with portal hypertension. The following sections will address some issues in this puzzle.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d95755e600>Decrease of portal pressure by shunt procedures</h2><p class="" id=d95755e603>The most effective measure to reduce portal hypertension is to circumvent the increased intrahepatic resistance in liver cirrhosis and bypass the blood into the inferior vena cava by portacaval, mesocaval, or proximal splenorenal shunts. Controlled trials evaluating the potential of a surgical open shunt procedure were mainly performed to assess their effect on the prevention of bleeding from varices. They date back to the 1960s<sup><a href="#ref-65">65</a>–<a href="#ref-67">67</a></sup>, but the most current long-term follow-up studies have been published as recently as 2012 and 2014<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>. The indication for open shunt procedures was almost exclusively prevention of bleeding. Although open surgical shunts may have advantages in young patients with severe portal hypertension, recurrent bleeding, and good liver function, this surgical procedure has been more or less abandoned and surgical experience is waning. This is mainly owing to its invasiveness, perioperative mortality, and an increased risk of liver failure and/or encephalopathy due to loss of liver perfusion with portal venous blood. Accordingly, it has never been convincingly shown that surgical shunts improve survival. By contrast, transjugular insertion of an intrahepatic stent between a branch of the portal vein and a branch of the hepatic vein (TIPS) is less invasive and has become an established treatment approach in portal hypertension and its complications. After a learning period in different pioneering centers<sup><a href="#ref-70">70</a></sup>, the procedure is now established worldwide. In most patients, TIPS implantation reduces portal pressure by more than 50%, as assessed by the portal pressure gradient. The degree of reduction depends on the diameter of the stent<sup><a href="#ref-36">36</a>,<a href="#ref-70">70</a></sup>. TIPS prevents variceal rebleeding in the vast majority of patients. According to many controlled trials and respective meta-analyses, TIPS is superior to ligation of varices with or without the addition of beta-blockers<sup><a href="#ref-71">71</a></sup>. Yet the combination of ligation and beta-blockers (see below) is still considered the procedure of choice for rebleeding prophylaxis<sup><a href="#ref-11">11</a></sup>, mainly because TIPS patients with decompensated cirrhosis (bilirubin &gt;3–5 mg/dL) are suboptimal candidates for shunt insertion, as they have a relatively high risk of liver and mental function deterioration. In the elective situation, TIPS implantation is therefore mainly used as a potential rescue procedure for the treatment of rebleeding of esophageal varices or the treatment of refractory ascites. According to randomized trials, around 20% of patients receiving local endoscopic rebleeding prophylaxis have to be switched to TIPS implantation because of refractory ascites or recurrent bleeding events<sup><a href="#ref-36">36</a>,<a href="#ref-72">72</a>–<a href="#ref-74">74</a></sup>. Thus, in patients with variceal bleeding and ascites, early placement of a small lumen-covered TIPS should be earnestly considered as early therapy.</p><p class="" id=d95755e650>One disadvantage of TIPS is shunt occlusions of bare stents, a rare event after shunt operation<sup><a href="#ref-75">75</a></sup>. However, this problem has been solved to a large extent by the introduction of polytetrafluoroethylene-covered stents<sup><a href="#ref-76">76</a>,<a href="#ref-77">77</a></sup>. Furthermore, there is evidence that the placement of small-diameter, covered stents (8 mm) reduces the encephalopathy rate<sup><a href="#ref-36">36</a>,<a href="#ref-78">78</a></sup>, while its protection from rebleeding remains. But, unfortunately, even small covered stents are still burdened with the risk of encephalopathy<sup><a href="#ref-36">36</a></sup>. Although TIPS insertion is now the most efficient method to reduce portal hypertension and to prevent bleeding in patients with liver cirrhosis, it does not improve survival as compared to patients receiving a non-shunt approach<sup><a href="#ref-71">71</a></sup>, at least in the elective situation. This also holds true for the most recent trials comparing non-selective beta-blockers (NSBB) with or without ligation to TIPS with covered stents<sup><a href="#ref-36">36</a>,<a href="#ref-73">73</a>,<a href="#ref-79">79</a></sup>.</p><p class="" id=d95755e690>Trials suggest that pre-emptive or “early” TIPS insertion is beneficial in high-risk patients, mainly those with active bleeding, decompensated liver cirrhosis, and/or HVPG &gt;20 mmHg<sup><a href="#ref-62">62</a>,<a href="#ref-80">80</a>,<a href="#ref-81">81</a></sup>, with respect to not only hemostasis and early rebleeding but also long-term survival. However, this strategy still needs to be established and proven in broad clinical practice. Currently, early TIPS insertion for acute variceal hemorrhage is neither always available nor widely applied in the real-world scenario<sup><a href="#ref-82">82</a></sup>. The positive effect of TIPS insertion for the prevention of bleeding in patients with liver cirrhosis declines with increasing temporal distance to the index bleeding event in the acute<sup><a href="#ref-83">83</a></sup> and elective<sup><a href="#ref-36">36</a></sup> situation, i.e. for the treatment of bleeding in patients with liver cirrhosis, suitable patients together with the appropriate time window<sup><a href="#ref-84">84</a></sup> have to be identified.</p><p class="" id=d95755e719>TIPS has a positive impact on hemodynamic changes in liver cirrhosis. Central blood volume and cardiac output increase after shunt placement<sup><a href="#ref-85">85</a>,<a href="#ref-86">86</a></sup>. This is associated with a deactivation of the renin–angiotensin–aldosterone system (RAAS) and improvement of impaired kidney sodium excretion in liver cirrhosis<sup><a href="#ref-70">70</a>,<a href="#ref-85">85</a>,<a href="#ref-87">87</a></sup>. It explains the positive effect of TIPS insertion for the mobilization of refractory ascites. While this method was initially developed to prevent intestinal hemorrhage in liver cirrhosis, the number of patients receiving stents for the treatment of ascites now surpasses the bleeding indication according to our own experience<sup><a href="#ref-53">53</a></sup> (unpublished data of groups from Bonn/Freiburg). There is an ongoing debate on the role of TIPS, especially with respect to the survival of ascitic patients, in comparison to paracentesis with albumin infusion<sup><a href="#ref-88">88</a></sup>. Analysis of the early studies using bare stents already suggested that TIPS improves transplant-free survival in patients with refractory ascites<sup><a href="#ref-89">89</a></sup>. A recent randomized study with limited patient numbers using covered stents showed a highly significant improvement of transplant-free survival in patients who had received covered TIPS for recurrent ascites when compared to paracentesis with albumin<sup><a href="#ref-90">90</a></sup>.</p><p class="" id=d95755e757>Taken together, TIPS, especially with technically improved stents, has become well established in the prevention and treatment of intestinal bleeding and ascites in patients with liver cirrhosis. However, the selection of patients is key. By contrast, hardly any centers exist that still perform shunt surgery for portal hypertension.</p><p class="" id=d95755e760>Shunts, including TIPS, bypass the increased hepatic resistance in patients with liver cirrhosis and exert their beneficial effect by a shift of the blood pool from the splanchnic to the central venous compartment. Most drugs, by contrast, act more by blunting stimuli that are activated or overactivated in liver cirrhosis. Some of these are addressed in the following paragraphs.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d95755e766>Modification of portal pressure by non-specific drugs</h2><p class="" id=d95755e769>New and old pathogenetic concepts showed that advanced liver cirrhosis with portal hypertension is a systemic disease involving most organs. It remains a challenge to counter this. The interruption of etiology is the most important step, mainly with respect to the progression of liver disease but also with respect to an immediate portal pressure-lowering effect. This holds true for the interruption of hepatitis C<sup><a href="#ref-91">91</a>–<a href="#ref-93">93</a></sup> or abstinence from alcohol<sup><a href="#ref-94">94</a></sup>. Since chronic alcoholism is now the most frequent cause of liver cirrhosis and portal hypertension in most countries, we need a more holistic approach to alcohol use disorders<sup><a href="#ref-95">95</a>,<a href="#ref-96">96</a></sup>.</p><p class="" id=d95755e790>In the following sections, we refer to medical treatments that are not curative but may have beneficial adjuvant effects.</p><div class=section><a name=d95755e793 class=n-a></a><h3 class=section-title>Non-selective beta-blockers (NSBB)</h3><p class="" id=d95755e798>The concept of treating portal hypertension with NSBB was introduced nearly four decades ago<sup><a href="#ref-1">1</a></sup> by a French group under the hypothesis that the portal tributary blood flow is increased in liver cirrhosis with portal hypertension and that NSBB decrease portal flow and pressure by reducing the cardiac index and splanchnic vasodilatation. The concept proved to be right, but the achieved reduction in portal pressure is only about 15% on average<sup><a href="#ref-36">36</a>,<a href="#ref-97">97</a></sup>. Numerous randomized controlled studies have documented the privileged place of NSBB in the treatment of portal hypertension, mainly for the prevention of first bleeding and, combined with endoscopic ligation, for recurrent bleeding<sup><a href="#ref-11">11</a>,<a href="#ref-98">98</a></sup>. However, for the prevention of first bleeding, sole ligation of esophageal varices is at least equivalent<sup><a href="#ref-99">99</a></sup> if not better<sup><a href="#ref-100">100</a></sup> than NSBB, especially in patients with large varices<sup><a href="#ref-11">11</a></sup>. The combination of NSBB and ligation has no advantage in this setting. Although it has been known since the mid-1990s<sup><a href="#ref-101">101</a></sup> that only patients with adequate pressure reduction (&gt;20% or to &lt;12 mmHg), as assessed by HVPG, are sufficiently protected from rebleeding, no suitable controlled studies have been published that address the question of whether the application of NSBB tailored by hemodynamic control (HVPG measurement) is superior to the application of NSBB in any patient for primary bleeding prophylaxis. Unfortunately, sufficient (&gt;20%) portal pressure reduction is achieved in only around 40% of patients<sup><a href="#ref-36">36</a>,<a href="#ref-102">102</a></sup>, and almost one-third of patients with liver cirrhosis have contraindications to NSBB, experience side effects, or are non-compliant<sup><a href="#ref-99">99</a></sup>.</p><p class="" id=d95755e847>A recent study on rebleeding prevention suggests that patients with liver cirrhosis who show a hemodynamic response to NSBB have an improved survival compared to those who fail to respond<sup><a href="#ref-103">103</a></sup>. However, the debate remains controversial as to whether or not the continuation of NSBB may even worsen the outcome in non-responders<sup><a href="#ref-104">104</a>,<a href="#ref-105">105</a></sup>. This has never been systematically evaluated. It is worth noting that it has been argued in this context that NSBB, besides their effect on splanchnic hemodynamics, modulate systemic inflammation in liver cirrhosis<sup><a href="#ref-106">106</a></sup>. This might explain why patients with cirrhosis and ACLF who had received NSBB within 3 months before admission (half of them were kept on NSBB also after admission) fared somewhat better than those without NSBB, but long-term survival was not different<sup><a href="#ref-107">107</a></sup>.</p><p class="" id=d95755e869>A French publication<sup><a href="#ref-108">108</a></sup> initiated the debate of whether NSBB should be omitted in patients with refractory ascites, in whom they may cause deleterious hemodynamic dysfunction, or in patients after infection of ascites<sup><a href="#ref-109">109</a></sup>. To date, most experts agree that only a systolic blood pressure below 90 mmHg and signs of worsening kidney function are caveats for continuation of NSBB<sup><a href="#ref-11">11</a></sup>, at least in higher dosages<sup><a href="#ref-110">110</a></sup>.</p><p class="" id=d95755e888>The type of NSBB for patients with liver cirrhosis has become an issue since it has been shown that, in patients with cirrhosis, carvedilol, a NSBB with additional alpha-1 adrenoceptor-blocking properties, induces a better hemodynamic response<sup><a href="#ref-97">97</a>,<a href="#ref-111">111</a></sup>, as determined by HVPG drop, than propranolol or nadolol and prevents the progression of small esophageal varices<sup><a href="#ref-112">112</a></sup>, an effect not found with propranolol. Retrospective data even asserted the prolongation of survival in patients with cirrhosis and ascites receiving carvedilol<sup><a href="#ref-113">113</a></sup>, while a recent letter analyzing several clinical studies drew the conclusion that carvedilol may even increase mortality compared to propranolol and nadolol<sup><a href="#ref-114">114</a></sup>. All this has to be considered with caution until sufficient randomized trials with predefined endpoints have been performed. Current data are too limited<sup><a href="#ref-115">115</a></sup>. Regardless of the NSBB type used, particular attention must be given to the hemodynamic status of a patient with liver cirrhosis, especially in the case of concomitant severe ascites, kidney dysfunction, reduced cardiac output, and/or infection.</p><p class="" id=d95755e915>In summary, NSBB kept their place for decades in the management of portal hypertension, mainly for the prevention of first or recurrent bleeding from varices. They may have an additional pleiotropic effect on reducing infectious stimuli from the gut. Caution is required in patients with severely decompensated cirrhosis or hemodynamic instability.</p></div><div class=section><a name=d95755e919 class=n-a></a><h3 class=section-title>Statins: a potential therapy for portal hypertension?</h3><p class="" id=d95755e924>NSBB primarily target the dysfunctional cardiovascular system outside the diseased liver. In the last two decades, clinical research has concentrated on the paradox that patients with liver cirrhosis exhibit splanchnic and systemic vasodilatation while their blood perfusion through the liver is hampered by an increased and unopposed activation of intrahepatic contractile cells, apart from structural changes due to fibrosis, capillarization of sinusoids, or regenerative nodules<sup><a href="#ref-116">116</a></sup>. A crucial step in this process is the activation and transdifferentiation of hepatic stellate cells in the space of Disse together with a dysfunction of sinusoidal cells<sup><a href="#ref-117">117</a></sup> caused by numerous different stimuli reaching the liver. Many more recent strategies for the treatment of portal hypertension aim to modulate this chronic intrahepatic hyper-responsive inflammatory process and its defects. Here, statins have been the focus for many years. There are numerous reports on the pleiotropic effects of these drugs apart from their LDL cholesterol-lowering benefit, some of which are relevant for liver disease<sup><a href="#ref-118">118</a>–<a href="#ref-121">121</a></sup>. Important among these are increased intrahepatic formation of the vasodilator nitric oxide<sup><a href="#ref-122">122</a></sup>, downregulation of signaling molecules that activate hepatic stellate cells<sup><a href="#ref-122">122</a>–<a href="#ref-124">124</a></sup> by reduced prenylation of small GTPases, modulation of the crosstalk between hepatic stellate cells and endothelial cells, upregulation of transcription factors that restore intrahepatic endothelial function<sup><a href="#ref-125">125</a></sup>, and downregulation of intrahepatic inflammatory cytokines<sup><a href="#ref-126">126</a>,<a href="#ref-127">127</a></sup>. All of these effects explain the reduction of intrahepatic resistance with a drop in portal pressure<sup><a href="#ref-122">122</a>,<a href="#ref-128">128</a>,<a href="#ref-129">129</a></sup> and blunting of collagen formation in experimental liver cirrhosis<sup><a href="#ref-123">123</a>,<a href="#ref-126">126</a>,<a href="#ref-127">127</a></sup>. A first randomized clinical trial on rebleeding prophylaxis in patients with liver cirrhosis who had succumbed to variceal hemorrhage could not confirm the hypothesis that the addition of statins to standard rebleeding prophylaxis (ligation and NSBB) further reduces the probability of rebleeding. However, compared to placebo, survival was better in the statin group<sup><a href="#ref-130">130</a></sup>. Mortality of the bleeding events and the infection rate were lower in patients receiving statins. This may be explained by the observation that statins have anti-inflammatory and immunomodulatory effects (for further details, see <a href="#ref-118">118</a>).</p><p class="" id=d95755e992>Large retrospective studies have shown that statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B- and hepatitis C-associated liver disease<sup><a href="#ref-131">131</a>–<a href="#ref-134">134</a></sup>, possibly because of their anti-inflammatory effect within the liver<sup><a href="#ref-126">126</a>,<a href="#ref-127">127</a></sup>. Thus, statins might primarily find their role as an adjuvant treatment to retard the progression of cirrhosis and portal hypertension with its complications in patients in whom a timely interruption of the etiology of chronic liver disease was not possible. In these patients, the potential hepatotoxicity of statins is a minor problem<sup><a href="#ref-135">135</a>,<a href="#ref-136">136</a></sup>. However, in patients with decompensated cirrhosis, particular attention must be paid to adverse events<sup><a href="#ref-130">130</a></sup>. Animal studies found that nitric oxide-donating statins may be as effective but less toxic<sup><a href="#ref-137">137</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d95755e1028>Modulation of the intestine</h2><p class="" id=d95755e1031>Intrahepatic resistance, portal tributary blood flow, and formation of spontaneous shunts determine portal pressure<sup><a href="#ref-116">116</a>,<a href="#ref-138">138</a></sup>. Intrahepatic resistance has a structural (fibrosis, alteration of the vascular architecture) and a non-structural (intrahepatic vascular tone) component. Gut-derived stimuli such as certain pathogen-associated molecular patterns (PAMPS) (lipopolysaccharide, endotoxin) may play an important role in this interplay. They impair intrahepatic endothelial function by influencing nitric oxide release<sup><a href="#ref-138">138</a>,<a href="#ref-139">139</a></sup> or stimulate signaling pathways of intrahepatic contractile cells and of fibrogenesis by inducing inflammation, e.g. activation of Kupffer cells and other macrophages<sup><a href="#ref-140">140</a>,<a href="#ref-141">141</a></sup> using sensing protein families such as Nod-like receptors or Toll-like receptors<sup><a href="#ref-142">142</a>,<a href="#ref-143">143</a></sup>. Especially in fatty liver disease, an early increase in portal pressure may be caused by functional non-structural changes of the intrahepatic vascular bed<sup><a href="#ref-144">144</a></sup>. Many questions in this context are not resolved. We will touch on some aspects in the following paragraphs.</p><p class="" id=d95755e1066>Alcohol is the most common cause of progressive liver dysfunction and portal hypertension in the Western world<sup><a href="#ref-145">145</a></sup>, although only a minority of heavy drinkers develop liver cirrhosis<sup><a href="#ref-146">146</a>,<a href="#ref-147">147</a></sup>. Early research on the mechanism of alcohol-induced liver damage focused on direct or indirect hepatotoxic effects of ethanol and its oxidative and non-oxidative metabolites, such as acetaldehyde or fatty acid ethyl esters<sup><a href="#ref-148">148</a></sup>. The handling of fatty acids by hepatocytes was also studied, since hepatic steatosis is an important pre-stage of alcoholic liver cirrhosis. There is abundant literature on this, but it is mostly based on animal and cell culture models. Later, endotoxin from the outer membrane of Gram-negative bacteria was more and more regarded as a cofactor for the pathogenesis of alcoholic liver disease<sup><a href="#ref-148">148</a>,<a href="#ref-149">149</a></sup> as a gut-derived stimulus. Further research showed that it mediates intrahepatic inflammation via Toll-like receptor 4 on macrophages<sup><a href="#ref-150">150</a></sup>, which in turn are a trigger for portal hypertension<sup><a href="#ref-140">140</a></sup>. Thus, the intestine has become a prime target for research on alcoholic liver disease and the catchword of today is gut–liver axis.</p><p class="" id=d95755e1100>Our intestine, mainly the colon, is host to an enormous number of microorganisms, such as bacteria, fungi, Archaea, and viruses<sup><a href="#ref-151">151</a></sup>. Most of these microorganisms are commensals with a symbiotic function. Their number equals the total amount of cells of our own body, and they create an internal ecosystem in addition to the surrounding world.</p><p class="" id=d95755e1107>Although high-throughput techniques, as an essential new step, are now broadly available to investigate the association of intestinal microorganisms with physiological phenomena or disease, the topic remains extremely complex regarding sample collection, analytical procedure, and evaluation of their functions as well as their integration and numerous interactions with human organs. Also, many bacterial metabolites<sup><a href="#ref-152">152</a></sup>, including dangerous ones, such as ammonia or hydrogen sulfide, and beneficial ones, such as short-chain fatty acids, must be considered. Last not least, T cells primed in the intestine can induce liver damage by aberrant homing in the liver<sup><a href="#ref-153">153</a></sup>. All of these different phenomena increase complexity. On the other hand, there is first evidence that common small molecules like N-acylamide with a signaling effect on G-protein-coupled receptors regulating metabolism are produced by human microbiota<sup><a href="#ref-154">154</a></sup>. Thus, in the end, a limited number of interacting biological structures may remain crucial.</p><p class="" id=d95755e1123>It has been shown that alcohol intake affects the integrity of the gut from an early stage, on the one hand by altering the intestinal microbiota, including the small bowel and the oral cavity<sup><a href="#ref-155">155</a>,<a href="#ref-156">156</a></sup>—often coined dysbiosis—and on the other hand by increasing intestinal permeability<sup><a href="#ref-157">157</a>,<a href="#ref-158">158</a></sup>. As yet, it remains unclear which is the “chicken” and which is the “egg”, but both phenomena give rise to an increased transfer of inflammatory stimuli to the liver, mediated via Toll-like receptors, and to alteration of the bile acid pool and its enterohepatic circulation (for further reading, see <a href="#ref-151">151</a>,<a href="#ref-159">159</a>,<a href="#ref-160">160</a>). Moreover, fungal dysbiosis has been incriminated in the induction of liver damage in alcohol abuse<sup><a href="#ref-161">161</a></sup>.</p><p class="" id=d95755e1154>A change in the individual bile acids by bacterial enzymes may lead to hepatobiliary injury via the induction of nuclear and G-protein-coupled cell surface receptors (see <a href="#ref-162">162</a>,<a href="#ref-163">163</a>). Based on these insights, numerous approaches, recently reviewed in depth<sup><a href="#ref-159">159</a>,<a href="#ref-164">164</a>–<a href="#ref-166">166</a></sup>, have been proposed to modulate the course of liver cirrhosis and portal hypertension.</p><p class="" id=d95755e1173>Since a distinct change of the microbiota with a reduction of autochthonous bacteria has been found in patients with liver cirrhosis compared to healthy individuals<sup><a href="#ref-167">167</a>,<a href="#ref-168">168</a></sup>, ongoing trials are targeting intestinal dysbiosis in patients with liver cirrhosis via antibiotics, probiotics, or synbiotics (see <a href="#ref-164">164</a>). Most of these trials study surrogate markers. Results on hard clinical endpoints, such as liver failure, bleeding, or death, are still far from being reached. One promising randomized study<sup><a href="#ref-169">169</a></sup> showed that the probiotic VSL#3 reduced liver disease severity and hospitalization in patients with mainly alcoholic liver cirrhosis in India. Another study from India found that administration of this probiotic increased the response rate to propranolol with respect to a decrease in HVPG<sup><a href="#ref-170">170</a></sup>.</p><p class="" id=d95755e1194>In patients with liver cirrhosis and variceal bleeding<sup><a href="#ref-171">171</a></sup> and in patients with decompensated liver cirrhosis<sup><a href="#ref-172">172</a>,<a href="#ref-173">173</a></sup>, systemic application of antibiotics, which affect other organs as well as the gut, increased survival. But direct studies on portal hemodynamics are sparse. Norfloxacin partially reversed the hyperdynamic state, while RAAS activation and portal hypertension were not influenced or only to a minor degree<sup><a href="#ref-174">174</a></sup>. Rifaximin is a non-absorbable antibiotic with proven effect on hepatic encephalopathy<sup><a href="#ref-175">175</a></sup>. While its effect in the intestine has not been fully elucidated, it has been found to reduce the production and absorption of gut-derived toxins and inflammatory stimuli, such as ammonia and endotoxin (see <a href="#ref-176">176</a>). Overall, its effects in the intestine may be more eubiotic than antibiotic<sup><a href="#ref-177">177</a></sup>. According to uncontrolled trials, rifaximin reduced plasma endotoxin levels and HVPG in alcohol-related decompensated liver cirrhosis<sup><a href="#ref-178">178</a></sup>. Furthermore, it lowered the 5-year cumulative probability of decompensation of cirrhosis, including bleeding and encephalopathy, and resulted in better survival<sup><a href="#ref-179">179</a></sup>. However, although the data are promising, they are from only one center and as yet remain uncontrolled. A randomized double-blind placebo-controlled trial consisting of a 4-week treatment with rifaximin found no effect on bacterial translocation, HVPG, systemic hemodynamics, kidney function, or vasoactive hormones, including plasma renin<sup><a href="#ref-180">180</a></sup>, and a further study found that there was no short-term effect of rifaximin on systemic inflammatory markers or intestinal bacterial composition<sup><a href="#ref-181">181</a></sup>.</p><p class="" id=d95755e1240>Alteration of the enterohepatic circulation of bile acids in liver and biliary disease<sup><a href="#ref-182">182</a>–<a href="#ref-184">184</a></sup> has also become a topic of research in portal hypertension (see above). Major regulators of bile acid homeostasis, such as the farnesoid X receptor (FXR) or TGR5<sup><a href="#ref-185">185</a>,<a href="#ref-186">186</a></sup>, are addressed by specific drugs. Two different research groups found that in animal models of cirrhosis, farnesoid receptor agonists reduced portal hypertension<sup><a href="#ref-187">187</a>,<a href="#ref-188">188</a></sup>. However, there is still a long way to go from proof of this concept in rats to an established treatment in the clinical situation. Bearing in mind that the FXR agonist obeticholic acid is already used in phase III trials<sup><a href="#ref-189">189</a></sup> for primary biliary cholangitis, particular emphasis should be given to determining to what extent these drugs may blunt portal hypertension and its complications. Further non-bile acid and non-steroidal FXR agonists with or without concomitant TGR5 activity are being tested in animal models<sup><a href="#ref-188">188</a>,<a href="#ref-190">190</a></sup>.</p><p class="" id=d95755e1275>It has been shown in animals, and now even in a small series of humans, that transplant of fecal microbiota may reverse hepatic disease or its symptoms<sup><a href="#ref-191">191</a></sup>. Furthermore, transplantation of stool from eubiotic rats to animals with a NASH model of portal hypertension significantly reduced portal pressure<sup><a href="#ref-144">144</a></sup>. However, to date, it is difficult to imagine that such an approach will have a future in clinical routine.</p><p class="" id=d95755e1287>Dysbiosis of the gut and alteration of intestinal permeability, which are associated with alcohol intake, affect not only the liver but also adipose tissue and the brain, with involvement of the autonomic nervous system as a regulating circuit, at least according to studies in animal models<sup><a href="#ref-192">192</a>–<a href="#ref-196">196</a></sup>. Activation of the immune system by the gut, including Toll-like receptor signaling, with release of proinflammatory cytokines is now regarded as a broad phenomenon that not only causes organ damage but also induces dysregulation in the brain, resulting in an unopposed craving for an unhealthy diet and liquids (see <a href="#ref-197">197</a>–<a href="#ref-199">199</a>). In this vicious cycle, portal hypertension presents as a late link to disease. Thus, it is eminently worthwhile to support beneficial change in the eating or drinking habits of patients, which are controlled by the brain. It has been shown that in patients with liver cirrhosis, weight loss<sup><a href="#ref-200">200</a></sup> or abstinence from alcohol<sup><a href="#ref-94">94</a>,<a href="#ref-201">201</a></sup> significantly reduces portal hypertension. This appears to be the most important strategy to influence the gut–liver axis and portal hypertension (<a href="#f1">Figure 1</a>).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d95755e1322>Other potential options and drugs</h2><p class="" id=d95755e1325>Patients with liver cirrhosis have an increased risk of portal vein thrombosis. The prevalence ranges from 10 to 20%, and the yearly incidence is estimated to be somewhat less than 10%<sup><a href="#ref-202">202</a></sup>. Anticoagulants reduce significantly the risk of occurrence<sup><a href="#ref-203">203</a></sup> and recurrence<sup><a href="#ref-204">204</a></sup>. One small randomized study found not only a significantly reduced occurrence of portal vein thrombosis but also fewer events of decompensation and even improved survival in patients with advanced cirrhosis receiving low-molecular-weight heparin over a period of nearly one year<sup><a href="#ref-203">203</a></sup>. The authors explain the positive effect by better microcirculation of the gut and less translocation of bacteria. Moreover, enoxaparin reduced intrahepatic vascular resistance and fibrosis in animal models of liver cirrhosis<sup><a href="#ref-205">205</a></sup>. Further studies on the putative beneficial effect of anticoagulation in patients with liver cirrhosis are needed.</p><p class="" id=d95755e1348>A recent comprehensive publication reviewed available studies on several other drugs that reduce portal hypertension, mostly in animal models<sup><a href="#ref-206">206</a></sup> and still in an experimental stage. In fact, many of these drugs reduce intrahepatic resistance. However, care has to be taken to prevent these drugs from aggravating hyperdynamic cardiovascular effects outside the liver<sup><a href="#ref-207">207</a>–<a href="#ref-209">209</a></sup> and from eliciting toxic effects inside the liver<sup><a href="#ref-210">210</a>–<a href="#ref-214">214</a></sup>. We have addressed this problem for many years<sup><a href="#ref-122">122</a>,<a href="#ref-215">215</a>–<a href="#ref-223">223</a></sup>. Unfortunately, clinical trials in humans are lacking. A search for the one panacea seems futile. The actual stage of portal hypertension and its etiology have to be considered. Interruption or suppression of viremia as a cause of chronic liver disease and portal hypertension is now possible for the hepatitis B as well as the hepatitis C virus. Thus, advanced liver disease and portal hypertension increasingly appear to be food-induced disorders rather than chronic infectious diseases. Here, the modulation of behavior is key, as it is the case with so many of the diseases of modern civilization. Drugs and interventions, however, retain their importance in treating the decompensated stage no matter whether initial etiology could be stopped or not (see above).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d95755e1382>Combined and stage-dependent treatment</h2><p class="" id=d95755e1385>At the stage of compensated cirrhosis without clinical signs of disease, it is crucial to halt progression. This is mainly achieved by interruption of an etiology that perpetuates inflammation and fibrogenesis leading to portal hypertension. Convincing examples include interruption or suppression of viremia, abstinence from alcohol abuse, immunosuppression of autoimmune liver disease, use of ursodeoxycholic acid in primary biliary cholangitis, or venesection for hemochromatosis. In all of these different etiologies, early diagnosis is important. However, co-factors (e.g. obesity, alcohol intake, or hepatotoxic drugs) which aggravate hepatic damage have to be considered and treated.</p><p class="" id=d95755e1388>Once portal hypertension has developed, as documented by the invasive or non-invasive methods outlined above, it is desirable to blunt its interaction with systemic hemodynamics and to prevent further organ dysfunction. This applies not only to the liver but also to the heart, kidneys, brain, and lungs. At this stage, reduction of portal hypertension by modulation of the intestine as a source of inflammatory stimuli or retarding inflammatory pathways may be promising strategies. Here, statins, NSBB, FXR agonists, probiotics, and antibiotics have been established or appear to be promising.</p><p class="" id=d95755e1391>In patients with ascites and variceal hemorrhage, early placement of a small lumen TIPS is an option because of its paramount effect on the prevention of bleeding and improvement of kidney function. However, once the stage of disease has become more advanced with threatening progress towards ACLF, survival is low and difficult to improve without liver transplantation. Thus, more effort must be put into early detection and prevention of liver disease, and more effective measures besides transplantation must be developed to treat decompensated cirrhosis. Combining small lumen TIPS with modulation of the systemic inflammatory response could be a possible approach.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d95755e1397>Conclusion</h2><p class="" id=d95755e1400>Portal hypertension is a surrogate of advanced liver disease. Reduction of portal pressure is the most efficient step to prevent intestinal bleeding and treat ascites. But this has a limited impact on survival. Interruption or modulation of inflammatory stimuli leading to liver damage and dysfunction of other organs is key in order to prevent death or liver transplantation as ultimate rescue.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d95755e1406>Abbreviations</h2><p class="" id=d95755e1409>ACLF, acute-on-chronic liver failure; ARFI, acoustic radiation force impulse imaging; FXR, farnesoid X receptor; HCC, hepatocellular carcinoma; HVPG, hepatic venous pressure gradient; MELD, model of end-stage liver disease; MR, magnetic resonance; MRI, magnetic resonance imaging; NSBB, non-selective beta-blockers; RAAS, renin–angiotensin–aldosterone system; SWE, shear wave elastography; TE, transient elastography; TIPS, transjugular intrahepatic portosystemic shunt.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d95755e1 class=n-a></a><h2 class=main-title id=d96388>Competing interests</h2><p class=metadata-entry><a name=d95755e114 class=n-a></a><p id=d95755e116> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d95755e1 class=n-a></a><h2 class=main-title id=d96390>Grant information</h2><p>This work was supported by Deutsche Forschungsgemeinschaft (SFB TRR57), the Cellex Foundation, and the European Union’s Horizon 2020 research and innovation program (No 668031).</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d95755e1416 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d97100>References</h2><div class="section ref-list"><a name=d95755e1416 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d95755e1423 class=n-a></a>Lebrec D, Nouel O, Corbic M, <i> et al.</i>: Propranolol--a medical treatment for portal hypertension? <i>Lancet.</i> 1980; <b>2</b>(8187): 180–2. <a target=xrefwindow id=d95755e1434 href="http://www.ncbi.nlm.nih.gov/pubmed/6105342">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1437 href="https://doi.org/10.1016/S0140-6736(80)90063-X">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d95755e1446 class=n-a></a>Møller S, Bendtsen F: The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. <i>Liver Int.</i> 2018; <b>38</b>(4): 570–80. <a target=xrefwindow id=d95755e1454 href="http://www.ncbi.nlm.nih.gov/pubmed/28921803">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1457 href="https://doi.org/10.1111/liv.13589">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d95755e1466 class=n-a></a>Wong F, Blendis L: New challenge of hepatorenal syndrome: prevention and treatment. <i>Hepatology.</i> 2001; <b>34</b>(6): 1242–51. <a target=xrefwindow id=d95755e1474 href="http://www.ncbi.nlm.nih.gov/pubmed/11732014">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1477 href="https://doi.org/10.1053/jhep.2001.29200">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d95755e1486 class=n-a></a>Moller S, Henriksen JH: Cardiopulmonary complications in chronic liver disease. <i>World J Gastroenterol.</i> 2006; <b>12</b>(4): 526–38. <a target=xrefwindow id=d95755e1494 href="http://www.ncbi.nlm.nih.gov/pubmed/16489664">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1497 href="https://doi.org/10.3748/wjg.v12.i4.526">Publisher Full Text </a> | <a target=xrefwindow id=d95755e1500 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4066083">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d95755e1509 class=n-a></a>Fallon MB, Abrams GA: Hepatopulmonary syndrome. <i>Curr Gastroenterol Rep.</i> 2000; <b>2</b>(1): 40–5. <a target=xrefwindow id=d95755e1517 href="http://www.ncbi.nlm.nih.gov/pubmed/10981002">PubMed Abstract </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d95755e1527 class=n-a></a>Macías-Rodríguez RU, Duarte-Rojo A, Cantú-Brito C, <i> et al.</i>: Cerebral haemodynamics in cirrhotic patients with hepatic encephalopathy. <i>Liver Int.</i> 2015; <b>35</b>(2): 344–52. <a target=xrefwindow id=d95755e1538 href="http://www.ncbi.nlm.nih.gov/pubmed/24690075">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1541 href="https://doi.org/10.1111/liv.12557">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d95755e1550 class=n-a></a>Mehta G, Mookerjee RP, Sharma V, <i> et al.</i>: Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure. <i>Liver Int.</i> 2015; <b>35</b>(3): 724–34. <a target=xrefwindow id=d95755e1561 href="http://www.ncbi.nlm.nih.gov/pubmed/24703488">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1564 href="https://doi.org/10.1111/liv.12559">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d95755e1573 class=n-a></a>Child CG, Turcotte JG: Surgery and portal hypertension. <i>Major Probl Clin Surg.</i> 1964; <b>1</b>: 1–85. <a target=xrefwindow id=d95755e1581 href="http://www.ncbi.nlm.nih.gov/pubmed/4950264">PubMed Abstract </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d95755e1590 class=n-a></a>D'Amico G, Garcia-Tsao G, Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. <i>J Hepatol.</i> 2006; <b>44</b>(1): 217–31. <a target=xrefwindow id=d95755e1598 href="http://www.ncbi.nlm.nih.gov/pubmed/16298014">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1601 href="https://doi.org/10.1016/j.jhep.2005.10.013">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d95755e1610 class=n-a></a>North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices: Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. <i>N Engl J Med.</i> 1988; <b>319</b>(15): 983–9. <a target=xrefwindow id=d95755e1618 href="http://www.ncbi.nlm.nih.gov/pubmed/3262200">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1621 href="https://doi.org/10.1056/NEJM198810133191505">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d95755e1630 class=n-a></a>de Franchis R, Baveno VI Faculty: Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. <i>J Hepatol.</i> 2015; <b>63</b>(3): 743–52. <a target=xrefwindow id=d95755e1638 href="http://www.ncbi.nlm.nih.gov/pubmed/26047908">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1641 href="https://doi.org/10.1016/j.jhep.2015.05.022">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d95755e1651 class=n-a></a>Bosch J, Sauerbruch T: Esophageal varices: Stage-dependent treatment algorithm. <i>J Hepatol.</i> 2016; <b>64</b>(3): 746–8. <a target=xrefwindow id=d95755e1659 href="http://www.ncbi.nlm.nih.gov/pubmed/26810377">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1662 href="https://doi.org/10.1016/j.jhep.2015.11.039">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717975913"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e1671 class=n-a></a>Berzigotti A, Seijo S, Arena U, <i> et al.</i>: Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. <i>Gastroenterology.</i> 2013; <b>144</b>(1): 102–111.e1. <a target=xrefwindow id=d95755e1682 href="http://www.ncbi.nlm.nih.gov/pubmed/23058320">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1685 href="https://doi.org/10.1053/j.gastro.2012.10.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717975913">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d95755e1698 class=n-a></a>Frulio N, Trillaud H: Ultrasound elastography in liver. <i>Diagn Interv Imaging.</i> 2013; <b>94</b>(5): 515–34. <a target=xrefwindow id=d95755e1706 href="http://www.ncbi.nlm.nih.gov/pubmed/23623211">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1709 href="https://doi.org/10.1016/j.diii.2013.02.005">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d95755e1718 class=n-a></a>Dietrich CF, Bamber J, Berzigotti A, <i> et al.</i>: EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). <i>Ultraschall Med.</i> 2017; <b>38</b>(4): e16–e47. <a target=xrefwindow id=d95755e1729 href="http://www.ncbi.nlm.nih.gov/pubmed/28407655">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1732 href="https://doi.org/10.1055/s-0043-103952">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d95755e1741 class=n-a></a>Ferraioli G, Filice C, Castera L, <i> et al.</i>: WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. <i>Ultrasound Med Biol.</i> 2015; <b>41</b>(5): 1161–79. <a target=xrefwindow id=d95755e1752 href="http://www.ncbi.nlm.nih.gov/pubmed/25800942">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1755 href="https://doi.org/10.1016/j.ultrasmedbio.2015.03.007">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d95755e1764 class=n-a></a>European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado: EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. <i>J Hepatol.</i> 2015; <b>63</b>(1): 237–64. <a target=xrefwindow id=d95755e1772 href="http://www.ncbi.nlm.nih.gov/pubmed/25911335">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1775 href="https://doi.org/10.1016/j.jhep.2015.04.006">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d95755e1785 class=n-a></a>Castera L: Non-invasive tests for liver fibrosis progression and regression. <i>J Hepatol.</i> 2016; <b>64</b>(1): 232–3. <a target=xrefwindow id=d95755e1793 href="http://www.ncbi.nlm.nih.gov/pubmed/26603523">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1796 href="https://doi.org/10.1016/j.jhep.2015.10.011">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d95755e1805 class=n-a></a>Herrmann E, de Lédinghen V, Cassinotto C, <i> et al.</i>: Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis. <i>Hepatology.</i> 2018; <b>67</b>(1): 260–72. <a target=xrefwindow id=d95755e1816 href="http://www.ncbi.nlm.nih.gov/pubmed/28370257">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1819 href="https://doi.org/10.1002/hep.29179">Publisher Full Text </a> | <a target=xrefwindow id=d95755e1823 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5765493">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d95755e1832 class=n-a></a>Kjærgaard M, Thiele M, Jansen C, <i> et al.</i>: High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal. <i>PLoS One.</i> 2017; <b>12</b>(4): e0173992. <a target=xrefwindow id=d95755e1843 href="http://www.ncbi.nlm.nih.gov/pubmed/28376114">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1846 href="https://doi.org/10.1371/journal.pone.0173992">Publisher Full Text </a> | <a target=xrefwindow id=d95755e1850 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5380309">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d95755e1859 class=n-a></a>Jansen C, Bogs C, Verlinden W, <i> et al.</i>: Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study. <i>Gut.</i> 2016; <b>65</b>(6): 1057–8. <a target=xrefwindow id=d95755e1870 href="http://www.ncbi.nlm.nih.gov/pubmed/26896458">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1873 href="https://doi.org/10.1136/gutjnl-2016-311536">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d95755e1882 class=n-a></a>Jansen C, Bogs C, Verlinden W, <i> et al.</i>: Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study. <i>Liver Int.</i> 2017; <b>37</b>(3): 396–405. <a target=xrefwindow id=d95755e1893 href="http://www.ncbi.nlm.nih.gov/pubmed/27569696">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1896 href="https://doi.org/10.1111/liv.13243">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732771428"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e1905 class=n-a></a>Kennedy P, Wagner M, Castéra L, <i> et al.</i>: Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. <i>Radiology.</i> 2018; <b>286</b>(3): 738–63. <a target=xrefwindow id=d95755e1916 href="http://www.ncbi.nlm.nih.gov/pubmed/29461949">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1919 href="https://doi.org/10.1148/radiol.2018170601">Publisher Full Text </a> | <a target=xrefwindow id=d95755e1923 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5831316">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732771428">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d95755e1937 class=n-a></a>Block W, Reichel C, Träber F, <i> et al.</i>: Effect of cytochrome P450 induction on phosphorus metabolites and proton relaxation times measured by <i>in vivo</i><sup>31</sup>P-magnetic resonance spectroscopy and <sup>1</sup>H-magnetic resonance relaxometry in human liver. <i>Hepatology.</i> 1997; <b>26</b>(6): 1587–91. <a target=xrefwindow id=d95755e1957 href="http://www.ncbi.nlm.nih.gov/pubmed/9398002">PubMed Abstract </a> | <a target=xrefwindow id=d95755e1960 href="https://doi.org/10.1002/hep.510260629">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d95755e1969 class=n-a></a>Reichel C, Block W, Skodra T, <i> et al.</i>: Relationship between cytochrome P-450 induction by rifampicin, hepatic volume and portal blood flow in man. <i>Eur J Gastroenterol Hepatol.</i> 1997; <b>9</b>(10): 975–9. <a target=xrefwindow id=d95755e1980 href="http://www.ncbi.nlm.nih.gov/pubmed/9391787">PubMed Abstract </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d95755e1989 class=n-a></a>Petitclerc L, Sebastiani G, Gilbert G, <i> et al.</i>: Liver fibrosis: Review of current imaging and MRI quantification techniques. <i>J Magn Reson Imaging.</i> 2017; <b>45</b>(5): 1276–95. <a target=xrefwindow id=d95755e2000 href="http://www.ncbi.nlm.nih.gov/pubmed/27981751">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2003 href="https://doi.org/10.1002/jmri.25550">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d95755e2012 class=n-a></a>Kukuk GM, Hittatiya K, Sprinkart AM, <i> et al.</i>: Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis. <i>Eur Radiol.</i> 2015; <b>25</b>(10): 2869–79. <a target=xrefwindow id=d95755e2023 href="http://www.ncbi.nlm.nih.gov/pubmed/25903702">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2026 href="https://doi.org/10.1007/s00330-015-3703-6">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d95755e2035 class=n-a></a>Luetkens JA, Klein S, Traeber F, <i> et al.</i>: Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study. <i>Gut.</i> 2018; <b>67</b>(3): 593–4. <a target=xrefwindow id=d95755e2046 href="http://www.ncbi.nlm.nih.gov/pubmed/28754777">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2049 href="https://doi.org/10.1136/gutjnl-2017-314561">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d95755e2058 class=n-a></a>Praktiknjo M, Book M, Luetkens J, <i> et al.</i>: Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis. <i>Hepatology.</i> 2018; <b>67</b>(3): 1014–26. <a target=xrefwindow id=d95755e2069 href="http://www.ncbi.nlm.nih.gov/pubmed/29059469">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2072 href="https://doi.org/10.1002/hep.29602">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d95755e2082 class=n-a></a>Groszmann RJ, Wongcharatrawee S: The hepatic venous pressure gradient: anything worth doing should be done right. <i>Hepatology.</i> 2004; <b>39</b>(2): 280–2. <a target=xrefwindow id=d95755e2090 href="http://www.ncbi.nlm.nih.gov/pubmed/14767976">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2093 href="https://doi.org/10.1002/hep.20062">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d95755e2102 class=n-a></a>Myers JD, Taylor WJ: Occlusive hepatic venous catheterization in the study of the normal liver, cirrhosis of the liver and noncirrhotic portal hypertension. <i>Circulation.</i> 1956; <b>13</b>(3): 368–80. <a target=xrefwindow id=d95755e2110 href="http://www.ncbi.nlm.nih.gov/pubmed/13356395">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2113 href="https://doi.org/10.1161/01.CIR.13.3.368">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d95755e2122 class=n-a></a>Groszmann RJ, Glickman M, Blei AT, <i> et al.</i>: Wedged and free hepatic venous pressure measured with a balloon catheter. <i>Gastroenterology.</i> 1979; <b>76</b>(2): 253–8. <a target=xrefwindow id=d95755e2133 href="http://www.ncbi.nlm.nih.gov/pubmed/759258">PubMed Abstract </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d95755e2142 class=n-a></a>Boyer TD, Triger DR, Horisawa M, <i> et al.</i>: Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure. <i>Gastroenterology.</i> 1977; <b>72</b>(4 Pt 1): 584–9. <a target=xrefwindow id=d95755e2153 href="http://www.ncbi.nlm.nih.gov/pubmed/838210">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2156 href="https://doi.org/10.1016/S0016-5085(77)80136-4">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d95755e2165 class=n-a></a>Brensing KA, Neubrand M, Textor J, <i> et al.</i>: Endoscopic manometry of esophageal varices: evaluation of a balloon technique compared with direct portal pressure measurement. <i>J Hepatol.</i> 1998; <b>29</b>(1): 94–102. <a target=xrefwindow id=d95755e2176 href="http://www.ncbi.nlm.nih.gov/pubmed/9696497">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2179 href="https://doi.org/10.1016/S0168-8278(98)80183-9">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d95755e2188 class=n-a></a>Bosch J, Abraldes JG, Berzigotti A, <i> et al.</i>: The clinical use of HVPG measurements in chronic liver disease. <i>Nat Rev Gastroenterol Hepatol.</i> 2009; <b>6</b>(10): 573–82. <a target=xrefwindow id=d95755e2199 href="http://www.ncbi.nlm.nih.gov/pubmed/19724251">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2202 href="https://doi.org/10.1038/nrgastro.2009.149">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d95755e2212 class=n-a></a>Sauerbruch T, Mengel M, Dollinger M, <i> et al.</i>: Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. <i>Gastroenterology.</i> 2015; <b>149</b>(3): 660–8.e1. <a target=xrefwindow id=d95755e2223 href="http://www.ncbi.nlm.nih.gov/pubmed/25989386">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2226 href="https://doi.org/10.1053/j.gastro.2015.05.011">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d95755e2235 class=n-a></a>Groszmann RJ, Garcia-Tsao G, Bosch J, <i> et al.</i>: Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. <i>N Engl J Med.</i> 2005; <b>353</b>(21): 2254–61. <a target=xrefwindow id=d95755e2246 href="http://www.ncbi.nlm.nih.gov/pubmed/16306522">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2249 href="https://doi.org/10.1056/NEJMoa044456">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d95755e2258 class=n-a></a>Boyer TD: Changing clinical practice with measurements of portal pressure. <i>Hepatology.</i> 2004; <b>39</b>(2): 283–5. <a target=xrefwindow id=d95755e2266 href="http://www.ncbi.nlm.nih.gov/pubmed/14767977">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2269 href="https://doi.org/10.1002/hep.20037">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726912111"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e2278 class=n-a></a>You MW, Kim KW, Pyo J, <i> et al.</i>: A Meta-analysis for the Diagnostic Performance of Transient Elastography for Clinically Significant Portal Hypertension. <i>Ultrasound Med Biol.</i> 2017; <b>43</b>(1): 59–68. <a target=xrefwindow id=d95755e2289 href="http://www.ncbi.nlm.nih.gov/pubmed/27751595">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2292 href="https://doi.org/10.1016/j.ultrasmedbio.2016.07.025">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726912111">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d95755e2305 class=n-a></a>Kim G, Kim MY, Baik SK: Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis. <i>Clin Mol Hepatol.</i> 2017; <b>23</b>(1): 34–41. <a target=xrefwindow id=d95755e2313 href="http://www.ncbi.nlm.nih.gov/pubmed/28263953">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2316 href="https://doi.org/10.3350/cmh.2016.0059">Publisher Full Text </a> | <a target=xrefwindow id=d95755e2319 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5381827">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d95755e2328 class=n-a></a>Pugh RN, Murray-Lyon IM, Dawson JL, <i> et al.</i>: Transection of the oesophagus for bleeding oesophageal varices. <i>Br J Surg.</i> 1973; <b>60</b>(8): 646–9. <a target=xrefwindow id=d95755e2339 href="http://www.ncbi.nlm.nih.gov/pubmed/4541913">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2342 href="https://doi.org/10.1002/bjs.1800600817">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d95755e2352 class=n-a></a>Kamath PS, Wiesner RH, Malinchoc M, <i> et al.</i>: A model to predict survival in patients with end-stage liver disease. <i>Hepatology.</i> 2001; <b>33</b>(2): 464–70. <a target=xrefwindow id=d95755e2363 href="http://www.ncbi.nlm.nih.gov/pubmed/11172350">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2366 href="https://doi.org/10.1053/jhep.2001.22172">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d95755e2375 class=n-a></a>Malinchoc M, Kamath PS, Gordon FD, <i> et al.</i>: A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. <i>Hepatology.</i> 2000; <b>31</b>(4): 864–71. <a target=xrefwindow id=d95755e2386 href="http://www.ncbi.nlm.nih.gov/pubmed/10733541">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2389 href="https://doi.org/10.1053/he.2000.5852">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d95755e2398 class=n-a></a>Schepke M, Roth F, Fimmers R, <i> et al.</i>: Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. <i>Am J Gastroenterol.</i> 2003; <b>98</b>(5): 1167–74. <a target=xrefwindow id=d95755e2409 href="http://www.ncbi.nlm.nih.gov/pubmed/12809844">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2412 href="https://doi.org/10.1111/j.1572-0241.2003.07515.x">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d95755e2421 class=n-a></a>Rudler M, Bureau C, Carbonell N, <i> et al.</i>: Recalibrated MELD and hepatic encephalopathy are prognostic factors in cirrhotic patients with acute variceal bleeding. <i>Liver Int.</i> 2018; <b>38</b>(3): 469–76. <a target=xrefwindow id=d95755e2432 href="http://www.ncbi.nlm.nih.gov/pubmed/29164762">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2435 href="https://doi.org/10.1111/liv.13632">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d95755e2444 class=n-a></a>Sharma P, Schaubel DE, Goodrich NP, <i> et al.</i>: Serum sodium and survival benefit of liver transplantation. <i>Liver Transpl.</i> 2015; <b>21</b>(3): 308–13. <a target=xrefwindow id=d95755e2455 href="http://www.ncbi.nlm.nih.gov/pubmed/25504743">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2458 href="https://doi.org/10.1002/lt.24063">Publisher Full Text </a> | <a target=xrefwindow id=d95755e2462 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4354811">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d95755e2471 class=n-a></a>van Vugt JLA, Alferink LJM, Buettner S, <i> et al.</i>: A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort. <i>J Hepatol.</i> 2018; <b>68</b>(4): 707–714, pii: S0168-8278(17)32474-1. <a target=xrefwindow id=d95755e2482 href="http://www.ncbi.nlm.nih.gov/pubmed/29221886">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2485 href="https://doi.org/10.1016/j.jhep.2017.11.030">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d95755e2495 class=n-a></a>Wong F, Liu P, Blendis L: Sodium homeostasis with chronic sodium loading in preascitic cirrhosis. <i>Gut.</i> 2001; <b>49</b>(6): 847–51. <a target=xrefwindow id=d95755e2503 href="http://www.ncbi.nlm.nih.gov/pubmed/11709521">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2506 href="https://doi.org/10.1136/gut.49.6.847">Publisher Full Text </a> | <a target=xrefwindow id=d95755e2509 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1728551">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d95755e2518 class=n-a></a>Wong F, O'Leary JG, Reddy KR, <i> et al.</i>: Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes. <i>Am J Gastroenterol.</i> 2017; <b>112</b>(7): 1103–10. <a target=xrefwindow id=d95755e2529 href="http://www.ncbi.nlm.nih.gov/pubmed/28440305">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2532 href="https://doi.org/10.1038/ajg.2017.122">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d95755e2541 class=n-a></a>Clària J, Stauber RE, Coenraad MJ, <i> et al.</i>: Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology.</i> 2016; <b>64</b>(4): 1249–64. <a target=xrefwindow id=d95755e2552 href="http://www.ncbi.nlm.nih.gov/pubmed/27483394">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2555 href="https://doi.org/10.1002/hep.28740">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d95755e2564 class=n-a></a>Hernaez R, Solà E, Moreau R, <i> et al.</i>: Acute-on-chronic liver failure: an update. <i>Gut.</i> 2017; <b>66</b>(3): 541–53. <a target=xrefwindow id=d95755e2575 href="http://www.ncbi.nlm.nih.gov/pubmed/28053053">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2578 href="https://doi.org/10.1136/gutjnl-2016-312670">Publisher Full Text </a> | <a target=xrefwindow id=d95755e2582 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5534763">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717988323"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e2591 class=n-a></a>Moreau R, Jalan R, Gines P, <i> et al.</i>: Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. <i>Gastroenterology.</i> 2013; <b>144</b>(7): 1426–37, 1437.e1–9. <a target=xrefwindow id=d95755e2602 href="http://www.ncbi.nlm.nih.gov/pubmed/23474284">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2605 href="https://doi.org/10.1053/j.gastro.2013.02.042">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717988323">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d95755e2618 class=n-a></a>Jansen C, Möller P, Meyer C, <i> et al.</i>: Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. <i>Hepatology.</i> 2018; <b>67</b>(4): 1472–84. <a target=xrefwindow id=d95755e2629 href="http://www.ncbi.nlm.nih.gov/pubmed/29059466">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2632 href="https://doi.org/10.1002/hep.29612">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d95755e2642 class=n-a></a>Alcaraz-Quiles J, Titos E, Casulleras M, <i> et al.</i>: Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure. <i>Hepatology.</i> 2017; <b>65</b>(1): 202–16. <a target=xrefwindow id=d95755e2653 href="http://www.ncbi.nlm.nih.gov/pubmed/27775822">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2656 href="https://doi.org/10.1002/hep.28896">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d95755e2665 class=n-a></a>Appenrodt B, Grünhage F, Gentemann MG, <i> et al.</i>: Nucleotide-binding oligomerization domain containing 2 (<i>NOD2</i>) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. <i>Hepatology.</i> 2010; <b>51</b>(4): 1327–33. <a target=xrefwindow id=d95755e2679 href="http://www.ncbi.nlm.nih.gov/pubmed/20087966">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2683 href="https://doi.org/10.1002/hep.23440">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d95755e2692 class=n-a></a>Lutz P, Krämer B, Kaczmarek DJ, <i> et al.</i>: A variant in the <i>nuclear dot protein 52kDa</i> gene increases the risk for spontaneous bacterial peritonitis in patients with alcoholic liver cirrhosis. <i>Dig Liver Dis.</i> 2016; <b>48</b>(1): 62–8. <a target=xrefwindow id=d95755e2706 href="http://www.ncbi.nlm.nih.gov/pubmed/26493630">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2710 href="https://doi.org/10.1016/j.dld.2015.09.011">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13432963"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e2719 class=n-a></a>Nischalke HD, Berger C, Aldenhoff K, <i> et al.</i>: Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. <i>J Hepatol.</i> 2011; <b>55</b>(5): 1010–6. <a target=xrefwindow id=d95755e2730 href="http://www.ncbi.nlm.nih.gov/pubmed/21356257">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2733 href="https://doi.org/10.1016/j.jhep.2011.02.022">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13432963">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d95755e2746 class=n-a></a>Trebicka J: Predisposing Factors in Acute-on-Chronic Liver Failure. <i>Semin Liver Dis.</i> 2016; <b>36</b>(2): 167–73. <a target=xrefwindow id=d95755e2754 href="http://www.ncbi.nlm.nih.gov/pubmed/27172359">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2757 href="https://doi.org/10.1055/s-0036-1583195">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d95755e2766 class=n-a></a>D'Amico G, Morabito A, D'Amico M, <i> et al.</i>: Clinical states of cirrhosis and competing risks. <i>J Hepatol.</i> 2018; <b>68</b>(3): 563–76. <a target=xrefwindow id=d95755e2777 href="http://www.ncbi.nlm.nih.gov/pubmed/29111320">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2780 href="https://doi.org/10.1016/j.jhep.2017.10.020">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d95755e2790 class=n-a></a>Rastogi A, Maiwall R, Bihari C, <i> et al.</i>: Cirrhosis histology and Laennec staging system correlate with high portal pressure. <i>Histopathology.</i> 2013; <b>62</b>(5): 731–41. <a target=xrefwindow id=d95755e2801 href="http://www.ncbi.nlm.nih.gov/pubmed/23470026">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2804 href="https://doi.org/10.1111/his.12070">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d95755e2813 class=n-a></a>Suk KT, Kim DJ: Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. <i>World J Hepatol.</i> 2015; <b>7</b>(3): 607–15. <a target=xrefwindow id=d95755e2821 href="http://www.ncbi.nlm.nih.gov/pubmed/25848485">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2824 href="https://doi.org/10.4254/wjh.v7.i3.607">Publisher Full Text </a> | <a target=xrefwindow id=d95755e2827 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4381184">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d95755e2836 class=n-a></a>Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, <i> et al.</i>: Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. <i>Hepatology.</i> 2004; <b>40</b>(4): 793–801. <a target=xrefwindow id=d95755e2847 href="http://www.ncbi.nlm.nih.gov/pubmed/15382120">PubMed Abstract </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d95755e2856 class=n-a></a>Moitinho E, Escorsell A, Bandi JC, <i> et al.</i>: Prognostic value of early measurements of portal pressure in acute variceal bleeding. <i>Gastroenterology.</i> 1999; <b>117</b>(3): 626–31. <a target=xrefwindow id=d95755e2867 href="http://www.ncbi.nlm.nih.gov/pubmed/10464138">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2870 href="https://doi.org/10.1016/S0016-5085(99)70455-5">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d95755e2879 class=n-a></a>Garcia-Tsao G, Friedman S, Iredale J, <i> et al.</i>: Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. <i>Hepatology.</i> 2010; <b>51</b>(4): 1445–9. <a target=xrefwindow id=d95755e2890 href="http://www.ncbi.nlm.nih.gov/pubmed/20077563">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2893 href="https://doi.org/10.1002/hep.23478">Publisher Full Text </a> | <a target=xrefwindow id=d95755e2897 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2882065">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d95755e2906 class=n-a></a>CONN HO, LINDENMUTH WW: PROPHYLACTIC PORTACAVAL ANASTOMOSIS IN CIRRHOTIC PATIENTS WITH ESOPHAGEAL VARICES: A PROGRESS REPORT OF A CONTINUING STUDY. <i>N Engl J Med.</i> 1965; <b>272</b>: 1255–63. <a target=xrefwindow id=d95755e2914 href="http://www.ncbi.nlm.nih.gov/pubmed/14290546">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2917 href="https://doi.org/10.1056/NEJM196506172722402">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d95755e2926 class=n-a></a>Resnick RH, Chalmers TC, Ishihara AM, <i> et al.</i>: A controlled study of the prophylactic portacaval shunt. A final report. <i>Ann Intern Med.</i> 1969; <b>70</b>(4): 675–88. <a target=xrefwindow id=d95755e2937 href="http://www.ncbi.nlm.nih.gov/pubmed/4890511">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2940 href="https://doi.org/10.7326/0003-4819-70-4-675">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d95755e2949 class=n-a></a>Franchis R de, Dell’Era A: Variceal Hemorrhage. Springer Science &amp; Business Media; 2014; 266. <a target=xrefwindow id=d95755e2951 href="https://doi.org/10.1007/978-1-4939-0002-2">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d95755e2960 class=n-a></a>Rosemurgy AS, Frohman HA, Teta AF, <i> et al.</i>: Prosthetic H-graft portacaval shunts vs transjugular intrahepatic portasystemic stent shunts: 18-year follow-up of a randomized trial. <i>J Am Coll Surg.</i> 2012; <b>214</b>(4): 445–53; discussion 453–5. <a target=xrefwindow id=d95755e2971 href="http://www.ncbi.nlm.nih.gov/pubmed/22463885">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2974 href="https://doi.org/10.1016/j.jamcollsurg.2011.12.042">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d95755e2983 class=n-a></a>Orloff MJ: Fifty-three years' experience with randomized clinical trials of emergency portacaval shunt for bleeding esophageal varices in Cirrhosis: 1958-2011. <i>JAMA Surg.</i> 2014; <b>149</b>(2): 155–69. <a target=xrefwindow id=d95755e2991 href="http://www.ncbi.nlm.nih.gov/pubmed/24402314">PubMed Abstract </a> | <a target=xrefwindow id=d95755e2994 href="https://doi.org/10.1001/jamasurg.2013.4045">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d95755e3003 class=n-a></a>Rössle M: TIPS: 25 years later. <i>J Hepatol.</i> 2013; <b>59</b>(5): 1081–93. <a target=xrefwindow id=d95755e3011 href="http://www.ncbi.nlm.nih.gov/pubmed/23811307">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3014 href="https://doi.org/10.1016/j.jhep.2013.06.014">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d95755e3023 class=n-a></a>Khan S, Tudur Smith C, Williamson P, <i> et al.</i>: Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. <i>Cochrane Database Syst Rev.</i> 2006; (4): CD000553. <a target=xrefwindow id=d95755e3031 href="http://www.ncbi.nlm.nih.gov/pubmed/17054131">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3034 href="https://doi.org/10.1002/14651858.CD000553.pub2">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d95755e3044 class=n-a></a>Holster IL, Tjwa ET, Moelker A, <i> et al.</i>: Reply. <i>Hepatology.</i> 2016; <b>64</b>(5): 1817–8. <a target=xrefwindow id=d95755e3055 href="http://www.ncbi.nlm.nih.gov/pubmed/27240057">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3058 href="https://doi.org/10.1002/hep.28664">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725891128"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3067 class=n-a></a>Holster IL, Tjwa ET, Moelker A, <i> et al.</i>: Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. <i>Hepatology.</i> 2016; <b>63</b>(2): 581–9. <a target=xrefwindow id=d95755e3078 href="http://www.ncbi.nlm.nih.gov/pubmed/26517576">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3081 href="https://doi.org/10.1002/hep.28318">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725891128">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d95755e3094 class=n-a></a>Luo X, Wang Z, Tsauo J, <i> et al.</i>: Advanced Cirrhosis Combined with Portal Vein Thrombosis: A Randomized Trial of TIPS versus Endoscopic Band Ligation Plus Propranolol for the Prevention of Recurrent Esophageal Variceal Bleeding. <i>Radiology.</i> 2015; <b>276</b>(1): 286–93. <a target=xrefwindow id=d95755e3105 href="http://www.ncbi.nlm.nih.gov/pubmed/25759969">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3108 href="https://doi.org/10.1148/radiol.15141252">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14605"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3117 class=n-a></a>Henderson JM, Boyer TD, Kutner MH, <i> et al.</i>: Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. <i>Gastroenterology.</i> 2006; <b>130</b>(6): 1643–51. <a target=xrefwindow id=d95755e3128 href="http://www.ncbi.nlm.nih.gov/pubmed/16697728">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3131 href="https://doi.org/10.1053/j.gastro.2006.02.008">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14605">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727624170"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3144 class=n-a></a>Gupta AC, Wang W, Shah C, <i> et al.</i>: Added Value of Covered Stents in Transjugular Intrahepatic Portosystemic Shunt: A Large Single-Center Experience. <i>Cardiovasc Intervent Radiol.</i> 2017; <b>40</b>(11): 1723–31. <a target=xrefwindow id=d95755e3155 href="http://www.ncbi.nlm.nih.gov/pubmed/28512687">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3158 href="https://doi.org/10.1007/s00270-017-1694-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727624170">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727512471"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3171 class=n-a></a>Qi X, Tian Y, Zhang W, <i> et al.</i>: Covered <i>versus</i> bare stents for transjugular intrahepatic portosystemic shunt: an updated meta-analysis of randomized controlled trials. <i>Therap Adv Gastroenterol.</i> 2017; <b>10</b>(1): 32–41. <a target=xrefwindow id=d95755e3185 href="http://www.ncbi.nlm.nih.gov/pubmed/28286557">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3189 href="https://doi.org/10.1177/1756283X16671286">Publisher Full Text </a> | <a target=xrefwindow id=d95755e3192 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5330607">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727512471">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727617972"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3206 class=n-a></a>Wang Q, Lv Y, Bai M, <i> et al.</i>: Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. <i>J Hepatol.</i> 2017; <b>67</b>(3): 508–16. <a target=xrefwindow id=d95755e3217 href="http://www.ncbi.nlm.nih.gov/pubmed/28506905">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3220 href="https://doi.org/10.1016/j.jhep.2017.05.006">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727617972">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d95755e3233 class=n-a></a>Qi X, Tian Y, Zhang W, <i> et al.</i>: Covered TIPS for secondary prophylaxis of variceal bleeding in liver cirrhosis: A systematic review and meta-analysis of randomized controlled trials. <i>Medicine (Baltimore).</i> 2016; <b>95</b>(50): e5680. <a target=xrefwindow id=d95755e3244 href="http://www.ncbi.nlm.nih.gov/pubmed/27977618">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3247 href="https://doi.org/10.1097/MD.0000000000005680">Publisher Full Text </a> | <a target=xrefwindow id=d95755e3251 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5268064">Free Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/4436956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3260 class=n-a></a>García-Pagán JC, Caca K, Bureau C, <i> et al.</i>: Early use of TIPS in patients with cirrhosis and variceal bleeding. <i>N Engl J Med.</i> 2010; <b>362</b>(25): 2370–9. <a target=xrefwindow id=d95755e3271 href="http://www.ncbi.nlm.nih.gov/pubmed/20573925">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3274 href="https://doi.org/10.1056/NEJMoa0910102">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/4436956">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/4436956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3287 class=n-a></a>Garcia-Pagán JC, Di Pascoli M, Caca K, <i> et al.</i>: Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. <i>J Hepatol.</i> 2013; <b>58</b>(1): 45–50. <a target=xrefwindow id=d95755e3298 href="http://www.ncbi.nlm.nih.gov/pubmed/22940408">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3301 href="https://doi.org/10.1016/j.jhep.2012.08.020">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/4436956">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d95755e3314 class=n-a></a>Thabut D, Pauwels A, Carbonell N, <i> et al.</i>: Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results. <i>J Hepatol.</i> 2017; <b>68</b>(1): 73–81. pii: S0168-8278(17)32281-X. <a target=xrefwindow id=d95755e3325 href="http://www.ncbi.nlm.nih.gov/pubmed/28918131">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3328 href="https://doi.org/10.1016/j.jhep.2017.09.002">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d95755e3337 class=n-a></a>Brensing KA, Raab P, Textor J, <i> et al.</i>: Prospective evaluation of a clinical score for 60-day mortality after transjugular intrahepatic portosystemic stent-shunt: Bonn TIPSS early mortality analysis. <i>Eur J Gastroenterol Hepatol.</i> 2002; <b>14</b>(7): 723–31. <a target=xrefwindow id=d95755e3348 href="http://www.ncbi.nlm.nih.gov/pubmed/12169980">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3351 href="https://doi.org/10.1097/00042737-200207000-00003">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d95755e3361 class=n-a></a>Trebicka J: Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close? <i>J Hepatol.</i> 2017; <b>66</b>(2): 442–50. <a target=xrefwindow id=d95755e3369 href="http://www.ncbi.nlm.nih.gov/pubmed/27984174">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3372 href="https://doi.org/10.1016/j.jhep.2016.10.025">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d95755e3381 class=n-a></a>Wong F, Sniderman K, Liu P, <i> et al.</i>: The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. <i>Gastroenterology.</i> 1997; <b>112</b>(3): 899–907. <a target=xrefwindow id=d95755e3392 href="http://www.ncbi.nlm.nih.gov/pubmed/9041252">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3395 href="https://doi.org/10.1053/gast.1997.v112.pm9041252">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732041615"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3404 class=n-a></a>Busk TM, Bendtsen F, Poulsen JH, <i> et al.</i>: Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. <i>Am J Physiol Gastrointest Liver Physiol.</i> 2018; <b>314</b>(2): G275–G286. <a target=xrefwindow id=d95755e3415 href="http://www.ncbi.nlm.nih.gov/pubmed/29074483">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3418 href="https://doi.org/10.1152/ajpgi.00094.2017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732041615">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d95755e3431 class=n-a></a>Brensing KA, Textor J, Perz J, <i> et al.</i>: Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. <i>Gut.</i> 2000; <b>47</b>(2): 288–95. <a target=xrefwindow id=d95755e3442 href="http://www.ncbi.nlm.nih.gov/pubmed/10896924">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3445 href="https://doi.org/10.1136/gut.47.2.288">Publisher Full Text </a> | <a target=xrefwindow id=d95755e3449 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1727992">Free Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d95755e3458 class=n-a></a>Sanyal AJ: Pros and cons of TIPS for refractory ascites. <i>J Hepatol.</i> 2005; <b>43</b>(6): 924–5. <a target=xrefwindow id=d95755e3466 href="http://www.ncbi.nlm.nih.gov/pubmed/16246451">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3469 href="https://doi.org/10.1016/j.jhep.2005.09.006">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d95755e3478 class=n-a></a>Salerno F, Cammà C, Enea M, <i> et al.</i>: Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. <i>Gastroenterology.</i> 2007; <b>133</b>(3): 825–34. <a target=xrefwindow id=d95755e3489 href="http://www.ncbi.nlm.nih.gov/pubmed/17678653">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3492 href="https://doi.org/10.1053/j.gastro.2007.06.020">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727494208"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3502 class=n-a></a>Bureau C, Thabut D, Oberti F, <i> et al.</i>: Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. <i>Gastroenterology.</i> 2017; <b>152</b>(1): 157–63. <a target=xrefwindow id=d95755e3513 href="http://www.ncbi.nlm.nih.gov/pubmed/27663604">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3516 href="https://doi.org/10.1053/j.gastro.2016.09.016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727494208">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d95755e3529 class=n-a></a>Lens S, Alvarado-Tapias E, Mariño Z, <i> et al.</i>: Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. <i>Gastroenterology.</i> 2017; <b>153</b>(5): 1273–1283.e1. <a target=xrefwindow id=d95755e3540 href="http://www.ncbi.nlm.nih.gov/pubmed/28734831">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3543 href="https://doi.org/10.1053/j.gastro.2017.07.016">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d95755e3552 class=n-a></a>Mandorfer M, Kozbial K, Freissmuth C, <i> et al.</i>: Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. <i>Aliment Pharmacol Ther.</i> 2015; <b>42</b>(6): 707–18. <a target=xrefwindow id=d95755e3563 href="http://www.ncbi.nlm.nih.gov/pubmed/26179884">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3566 href="https://doi.org/10.1111/apt.13315">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d95755e3575 class=n-a></a>Mandorfer M, Kozbial K, Schwabl P, <i> et al.</i>: Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. <i>J Hepatol.</i> 2016; <b>65</b>(4): 692–9. <a target=xrefwindow id=d95755e3586 href="http://www.ncbi.nlm.nih.gov/pubmed/27242316">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3589 href="https://doi.org/10.1016/j.jhep.2016.05.027">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d95755e3598 class=n-a></a>Klein CP, Kalk JF, Müting D, <i> et al.</i>: [The effect of alcohol on portal vein hemodynamics in nutritional-toxic liver cirrhosis]. <i>Dtsch Med Wochenschr.</i> 1993; <b>118</b>(4): 89–93. <a target=xrefwindow id=d95755e3609 href="http://www.ncbi.nlm.nih.gov/pubmed/8428561">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3612 href="https://doi.org/10.1055/s-2008-1059304">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d95755e3621 class=n-a></a>Vaillant GE: A 60-year follow-up of alcoholic men. <i>Addiction.</i> 2003; <b>98</b>(8): 1043–51. <a target=xrefwindow id=d95755e3629 href="http://www.ncbi.nlm.nih.gov/pubmed/12873238">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3632 href="https://doi.org/10.1046/j.1360-0443.2003.00422.x">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d95755e3642 class=n-a></a>Vaillant GE: The Natural History of Alcoholism Revisited. Harvard University Press; 2009; 463. <a target=xrefwindow id=d95755e3644 href="https://books.google.co.in/books?id=5t19rq4QRPsC&amp;printsec=frontcover&amp;source=gbs_ge_summary_r&amp;cad=0#v=onepage&amp;q&amp;f=false">Reference Source</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d95755e3653 class=n-a></a>Sinagra E, Perricone G, D'Amico M, <i> et al.</i>: Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. <i>Aliment Pharmacol Ther.</i> 2014; <b>39</b>(6): 557–68. <a target=xrefwindow id=d95755e3664 href="http://www.ncbi.nlm.nih.gov/pubmed/24461301">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3667 href="https://doi.org/10.1111/apt.12634">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d95755e3676 class=n-a></a>Mandorfer M, Reiberger T: Beta blockers and cirrhosis, 2016. <i>Dig Liver Dis.</i> 2017; <b>49</b>(1): 3–10. <a target=xrefwindow id=d95755e3684 href="http://www.ncbi.nlm.nih.gov/pubmed/27717792">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3687 href="https://doi.org/10.1016/j.dld.2016.09.013">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d95755e3696 class=n-a></a>Schepke M, Kleber G, Nürnberg D, <i> et al.</i>: Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. <i>Hepatology.</i> 2004; <b>40</b>(1): 65–72. <a target=xrefwindow id=d95755e3707 href="http://www.ncbi.nlm.nih.gov/pubmed/15239087">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3710 href="https://doi.org/10.1002/hep.20284">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d95755e3719 class=n-a></a>Gluud LL, Krag A: Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. <i>Cochrane Database Syst Rev.</i> 2012; (8): CD004544. <a target=xrefwindow id=d95755e3724 href="http://www.ncbi.nlm.nih.gov/pubmed/22895942">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3727 href="https://doi.org/10.1002/14651858.CD004544.pub2">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d95755e3736 class=n-a></a>Feu F, García-Pagán JC, Bosch J, <i> et al.</i>: Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. <i>Lancet.</i> 1995; <b>346</b>(8982): 1056–9. <a target=xrefwindow id=d95755e3747 href="http://www.ncbi.nlm.nih.gov/pubmed/7564785">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3750 href="https://doi.org/10.1016/S0140-6736(95)91740-3">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d95755e3760 class=n-a></a>D'Amico G, Garcia-Pagan JC, Luca A, <i> et al.</i>: Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. <i>Gastroenterology.</i> 2006; <b>131</b>(5): 1611–24. <a target=xrefwindow id=d95755e3771 href="http://www.ncbi.nlm.nih.gov/pubmed/17101332">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3774 href="https://doi.org/10.1053/j.gastro.2006.09.013">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727218458"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3783 class=n-a></a>Villanueva C, Graupera I, Aracil C, <i> et al.</i>: A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis. <i>Hepatology.</i> 2017; <b>65</b>(5): 1693–707. <a target=xrefwindow id=d95755e3794 href="http://www.ncbi.nlm.nih.gov/pubmed/28100019">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3797 href="https://doi.org/10.1002/hep.29056">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727218458">F1000 Recommendation</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d95755e3810 class=n-a></a>Sauerbruch T: Continuation of nonselective beta-blockers for patients with liver cirrhosis and hemodynamic nonresponse? <i>Hepatology.</i> 2017; <b>66</b>(4): 1362–3. <a target=xrefwindow id=d95755e3818 href="http://www.ncbi.nlm.nih.gov/pubmed/28734120">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3821 href="https://doi.org/10.1002/hep.29394">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d95755e3830 class=n-a></a>Villanueva C, Graupera I, Alvarado E: Reply. <i>Hepatology.</i> 2017; <b>66</b>(4): 1363–4. <a target=xrefwindow id=d95755e3838 href="http://www.ncbi.nlm.nih.gov/pubmed/28741289">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3841 href="https://doi.org/10.1002/hep.29397">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d95755e3850 class=n-a></a>Madsen BS, Havelund T, Krag A: Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. <i>Adv Ther.</i> 2013; <b>30</b>(7): 659–70. <a target=xrefwindow id=d95755e3858 href="http://www.ncbi.nlm.nih.gov/pubmed/23881723">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3861 href="https://doi.org/10.1007/s12325-013-0044-1">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d95755e3870 class=n-a></a>Mookerjee RP, Pavesi M, Thomsen KL, <i> et al.</i>: Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. <i>J Hepatol.</i> 2016; <b>64</b>(3): 574–82. <a target=xrefwindow id=d95755e3881 href="http://www.ncbi.nlm.nih.gov/pubmed/26519600">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3884 href="https://doi.org/10.1016/j.jhep.2015.10.018">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/5622963"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3894 class=n-a></a>Sersté T, Melot C, Francoz C, <i> et al.</i>: Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. <i>Hepatology.</i> 2010; <b>52</b>(3): 1017–22. <a target=xrefwindow id=d95755e3905 href="http://www.ncbi.nlm.nih.gov/pubmed/20583214">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3908 href="https://doi.org/10.1002/hep.23775">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/5622963">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718312310"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3921 class=n-a></a>Mandorfer M, Bota S, Schwabl P, <i> et al.</i>: Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. <i>Gastroenterology.</i> 2014; <b>146</b>(7): 1680–90.e1. <a target=xrefwindow id=d95755e3932 href="http://www.ncbi.nlm.nih.gov/pubmed/24631577">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3935 href="https://doi.org/10.1053/j.gastro.2014.03.005">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718312310">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726994159"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3948 class=n-a></a>Reiberger T, Mandorfer M: Beta adrenergic blockade and decompensated cirrhosis. <i>J Hepatol.</i> 2017; <b>66</b>(4): 849–59. <a target=xrefwindow id=d95755e3956 href="http://www.ncbi.nlm.nih.gov/pubmed/27864004">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3959 href="https://doi.org/10.1016/j.jhep.2016.11.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726994159">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718158968"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3972 class=n-a></a>Reiberger T, Ulbrich G, Ferlitsch A, <i> et al.</i>: Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut.</i> 2013; <b>62</b>(11): 1634–41. <a target=xrefwindow id=d95755e3983 href="http://www.ncbi.nlm.nih.gov/pubmed/23250049">PubMed Abstract </a> | <a target=xrefwindow id=d95755e3986 href="https://doi.org/10.1136/gutjnl-2012-304038">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718158968">F1000 Recommendation</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726421771"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e3999 class=n-a></a>Bhardwaj A, Kedarisetty CK, Vashishtha C, <i> et al.</i>: Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. <i>Gut.</i> 2017; <b>66</b>(10): 1838–43. <a target=xrefwindow id=d95755e4010 href="http://www.ncbi.nlm.nih.gov/pubmed/27298379">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4013 href="https://doi.org/10.1136/gutjnl-2016-311735">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726421771">F1000 Recommendation</a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d95755e4026 class=n-a></a>Sinha R, Lockman KA, Mallawaarachchi N, <i> et al.</i>: Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. <i>J Hepatol.</i> 2017; <b>67</b>(1): 40–6. <a target=xrefwindow id=d95755e4037 href="http://www.ncbi.nlm.nih.gov/pubmed/28213164">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4040 href="https://doi.org/10.1016/j.jhep.2017.02.005">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d95755e4050 class=n-a></a>Njei B, McCarty TR, Garcia-Tsao G: Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. <i>Gut.</i> 2016; <b>65</b>(8): 1393–4. <a target=xrefwindow id=d95755e4058 href="http://www.ncbi.nlm.nih.gov/pubmed/27207973">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4061 href="https://doi.org/10.1136/gutjnl-2016-312129">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d95755e4070 class=n-a></a>Li T, Ke W, Sun P, <i> et al.</i>: Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. <i>BMJ Open.</i> 2016; <b>6</b>(5): e010902. <a target=xrefwindow id=d95755e4081 href="http://www.ncbi.nlm.nih.gov/pubmed/27147389">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4084 href="https://doi.org/10.1136/bmjopen-2015-010902">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4088 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4861122">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d95755e4097 class=n-a></a>Groszmann RJ, Bosch J: Portal Hypertension in the 21st Century: The proceedings of a symposium sponsored by Axcan Pharma Inc. and NicOx S.A., held in Montrél, Canada, April 2–4, 2004. Springer Science &amp; Business Media; 2011; 366. <a target=xrefwindow id=d95755e4099 href="https://doi.org/10.1007/978-94-007-1042-9">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d95755e4108 class=n-a></a>Bosch J, Groszmann RJ, Shah VH: Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. <i>J Hepatol.</i> 2015; <b>62</b>(1 Suppl): S121–30. <a target=xrefwindow id=d95755e4116 href="http://www.ncbi.nlm.nih.gov/pubmed/25920081">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4119 href="https://doi.org/10.1016/j.jhep.2015.01.003">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4122 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4519833">Free Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d95755e4131 class=n-a></a>Bedi O, Dhawan V, Sharma PL, <i> et al.</i>: Pleiotropic effects of statins: new therapeutic targets in drug design. <i>Naunyn Schmiedebergs Arch Pharmacol.</i> 2016; <b>389</b>(7): 695–712. <a target=xrefwindow id=d95755e4142 href="http://www.ncbi.nlm.nih.gov/pubmed/27146293">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4145 href="https://doi.org/10.1007/s00210-016-1252-4">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d95755e4154 class=n-a></a>Oesterle A, Laufs U, Liao JK: Pleiotropic Effects of Statins on the Cardiovascular System. <i>Circ Res.</i> 2017; <b>120</b>(1): 229–43. <a target=xrefwindow id=d95755e4162 href="http://www.ncbi.nlm.nih.gov/pubmed/28057795">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4165 href="https://doi.org/10.1161/CIRCRESAHA.116.308537">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4168 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5467317">Free Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d95755e4178 class=n-a></a>Schierwagen R, Uschner FE, Magdaleno F, <i> et al.</i>: Rationale for the use of statins in liver disease. <i>Am J Physiol Gastrointest Liver Physiol.</i> 2017; <b>312</b>(5): G407–G412. <a target=xrefwindow id=d95755e4189 href="http://www.ncbi.nlm.nih.gov/pubmed/28280144">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4192 href="https://doi.org/10.1152/ajpgi.00441.2016">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d95755e4201 class=n-a></a>Trebicka J, Schierwagen R: Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. <i>Gut.</i> 2015; <b>64</b>(9): 1349–50. <a target=xrefwindow id=d95755e4209 href="http://www.ncbi.nlm.nih.gov/pubmed/25596180">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4212 href="https://doi.org/10.1136/gutjnl-2014-308800">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d95755e4221 class=n-a></a>Trebicka J, Hennenberg M, Laleman W, <i> et al.</i>: Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. <i>Hepatology.</i> 2007; <b>46</b>(1): 242–53. <a target=xrefwindow id=d95755e4232 href="http://www.ncbi.nlm.nih.gov/pubmed/17596891">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4235 href="https://doi.org/10.1002/hep.21673">Publisher Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d95755e4244 class=n-a></a>Rombouts K, Kisanga E, Hellemans K, <i> et al.</i>: Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. <i>J Hepatol.</i> 2003; <b>38</b>(5): 564–72. <a target=xrefwindow id=d95755e4255 href="http://www.ncbi.nlm.nih.gov/pubmed/12713866">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4258 href="https://doi.org/10.1016/S0168-8278(03)00051-5">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d95755e4267 class=n-a></a>Uschner FE, Ranabhat G, Choi SS, <i> et al.</i>: Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. <i>Sci Rep.</i> 2015; <b>5</b>: 14573. <a target=xrefwindow id=d95755e4278 href="http://www.ncbi.nlm.nih.gov/pubmed/26412302">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4281 href="https://doi.org/10.1038/srep14573">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4285 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4585958">Free Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d95755e4294 class=n-a></a>Marrone G, Maeso-Díaz R, García-Cardena G, <i> et al.</i>: KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. <i>Gut.</i> 2015; <b>64</b>(9): 1434–43. <a target=xrefwindow id=d95755e4305 href="http://www.ncbi.nlm.nih.gov/pubmed/25500203">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4308 href="https://doi.org/10.1136/gutjnl-2014-308338">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d95755e4318 class=n-a></a>Trebicka J, Hennenberg M, Odenthal M, <i> et al.</i>: Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. <i>J Hepatol.</i> 2010; <b>53</b>(4): 702–12. <a target=xrefwindow id=d95755e4329 href="http://www.ncbi.nlm.nih.gov/pubmed/20633948">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4332 href="https://doi.org/10.1016/j.jhep.2010.04.025">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d95755e4341 class=n-a></a>Klein S, Klösel J, Schierwagen R, <i> et al.</i>: Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. <i>Lab Invest.</i> 2012; <b>92</b>(10): 1440–50. <a target=xrefwindow id=d95755e4352 href="http://www.ncbi.nlm.nih.gov/pubmed/22890553">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4355 href="https://doi.org/10.1038/labinvest.2012.106">Publisher Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718874829"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4364 class=n-a></a>Zafra C, Abraldes JG, Turnes J, <i> et al.</i>: Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. <i>Gastroenterology.</i> 2004; <b>126</b>(3): 749–55. <a target=xrefwindow id=d95755e4375 href="http://www.ncbi.nlm.nih.gov/pubmed/14988829">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4378 href="https://doi.org/10.1053/j.gastro.2003.12.007">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718874829">F1000 Recommendation</a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1158319"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4391 class=n-a></a>Abraldes JG, Albillos A, Bañares R, <i> et al.</i>: Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. <i>Gastroenterology.</i> 2009; <b>136</b>(5): 1651–8. <a target=xrefwindow id=d95755e4402 href="http://www.ncbi.nlm.nih.gov/pubmed/19208350">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4405 href="https://doi.org/10.1053/j.gastro.2009.01.043">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1158319">F1000 Recommendation</a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726079867"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4418 class=n-a></a>Abraldes JG, Villanueva C, Aracil C, <i> et al.</i>: Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology.</i> 2016; <b>150</b>(5): 1160–1170.e3. <a target=xrefwindow id=d95755e4429 href="http://www.ncbi.nlm.nih.gov/pubmed/26774179">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4432 href="https://doi.org/10.1053/j.gastro.2016.01.004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726079867">F1000 Recommendation</a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727423169"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4445 class=n-a></a>Chang FM, Wang YP, Lang HC, <i> et al.</i>: Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study. <i>Hepatology.</i> 2017; <b>66</b>(3): 896–907. <a target=xrefwindow id=d95755e4456 href="http://www.ncbi.nlm.nih.gov/pubmed/28318053">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4459 href="https://doi.org/10.1002/hep.29172">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727423169">F1000 Recommendation</a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726347016"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4473 class=n-a></a>Huang YW, Lee CL, Yang SS, <i> et al.</i>: Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. <i>Am J Gastroenterol.</i> 2016; <b>111</b>(7): 976–85. <a target=xrefwindow id=d95755e4484 href="http://www.ncbi.nlm.nih.gov/pubmed/27166128">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4487 href="https://doi.org/10.1038/ajg.2016.179">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726347016">F1000 Recommendation</a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725860590"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4500 class=n-a></a>Mohanty A, Tate JP, Garcia-Tsao G: Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis. <i>Gastroenterology.</i> 2016; <b>150</b>(2): 430–40.e1. <a target=xrefwindow id=d95755e4508 href="http://www.ncbi.nlm.nih.gov/pubmed/26484707">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4511 href="https://doi.org/10.1053/j.gastro.2015.10.007">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4514 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4727998">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725860590">F1000 Recommendation</a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726155359"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4527 class=n-a></a>Simon TG, Bonilla H, Yan P, <i> et al.</i>: Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. <i>Hepatology.</i> 2016; <b>64</b>(1): 47–57. <a target=xrefwindow id=d95755e4538 href="http://www.ncbi.nlm.nih.gov/pubmed/26891205">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4541 href="https://doi.org/10.1002/hep.28506">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4545 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4917438">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726155359">F1000 Recommendation</a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1095039"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4558 class=n-a></a>Lewis JH, Mortensen ME, Zweig S, <i> et al.</i>: Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. <i>Hepatology.</i> 2007; <b>46</b>(5): 1453–63. <a target=xrefwindow id=d95755e4569 href="http://www.ncbi.nlm.nih.gov/pubmed/17668878">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4572 href="https://doi.org/10.1002/hep.21848">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1095039">F1000 Recommendation</a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d95755e4585 class=n-a></a>Chalasani N, Aljadhey H, Kesterson J, <i> et al.</i>: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. <i>Gastroenterology.</i> 2004; <b>126</b>(5): 1287–92. <a target=xrefwindow id=d95755e4596 href="http://www.ncbi.nlm.nih.gov/pubmed/15131789">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4599 href="https://doi.org/10.1053/j.gastro.2004.02.015">Publisher Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727203176"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4608 class=n-a></a>Rodríguez S, Raurell I, Torres-Arauz M, <i> et al.</i>: A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats. <i>Sci Rep.</i> 2017; <b>7</b>: 40461. <a target=xrefwindow id=d95755e4619 href="http://www.ncbi.nlm.nih.gov/pubmed/28084470">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4622 href="https://doi.org/10.1038/srep40461">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4626 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5233977">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727203176">F1000 Recommendation</a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d95755e4640 class=n-a></a>McConnell M, Iwakiri Y: Biology of portal hypertension. <i>Hepatol Int.</i> 2018; <b>12</b>(Suppl 1): 11–23. <a target=xrefwindow id=d95755e4648 href="http://www.ncbi.nlm.nih.gov/pubmed/29075990">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4651 href="https://doi.org/10.1007/s12072-017-9826-x">Publisher Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d95755e4660 class=n-a></a>Pasarín M, La Mura V, Gracia-Sancho J, <i> et al.</i>: Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. <i>PLoS One.</i> 2012; <b>7</b>(4): e32785. <a target=xrefwindow id=d95755e4671 href="http://www.ncbi.nlm.nih.gov/pubmed/22509248">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4674 href="https://doi.org/10.1371/journal.pone.0032785">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4678 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3317918">Free Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d95755e4687 class=n-a></a>Steib CJ, Schewe J, Gerbes AL: Infection as a Trigger for Portal Hypertension. <i>Dig Dis.</i> 2015; <b>33</b>(4): 570–6. <a target=xrefwindow id=d95755e4695 href="http://www.ncbi.nlm.nih.gov/pubmed/26159275">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4698 href="https://doi.org/10.1159/000375352">Publisher Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d95755e4707 class=n-a></a>Grønbaek H, Sandahl TD, Mortensen C, <i> et al.</i>: Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. <i>Aliment Pharmacol Ther.</i> 2012; <b>36</b>(2): 173–80. <a target=xrefwindow id=d95755e4718 href="http://www.ncbi.nlm.nih.gov/pubmed/22591184">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4721 href="https://doi.org/10.1111/j.1365-2036.2012.05134.x">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13642956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4730 class=n-a></a>Henao-Mejia J, Elinav E, Jin C, <i> et al.</i>: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. <i>Nature.</i> 2012; <b>482</b>(7384): 179–85. <a target=xrefwindow id=d95755e4741 href="http://www.ncbi.nlm.nih.gov/pubmed/22297845">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4744 href="https://doi.org/10.1038/nature10809">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4748 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3276682">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13642956">F1000 Recommendation</a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1158423"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4761 class=n-a></a>Guo J, Loke J, Zheng F, <i> et al.</i>: Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. <i>Hepatology.</i> 2009; <b>49</b>(3): 960–8. <a target=xrefwindow id=d95755e4772 href="http://www.ncbi.nlm.nih.gov/pubmed/19085953">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4775 href="https://doi.org/10.1002/hep.22697">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4779 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2891538">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1158423">F1000 Recommendation</a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732084352"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e4793 class=n-a></a>García-Lezana T, Raurell I, Bravo M, <i> et al.</i>: Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. <i>Hepatology.</i> 2018; <b>67</b>(4): 1485–98. <a target=xrefwindow id=d95755e4804 href="http://www.ncbi.nlm.nih.gov/pubmed/29113028">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4807 href="https://doi.org/10.1002/hep.29646">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732084352">F1000 Recommendation</a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d95755e4820 class=n-a></a>Harris R, Harman DJ, Card TR, <i> et al.</i>: Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. <i>Lancet Gastroenterol Hepatol.</i> 2017; <b>2</b>(4): 288–97. <a target=xrefwindow id=d95755e4831 href="http://www.ncbi.nlm.nih.gov/pubmed/28404158">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4834 href="https://doi.org/10.1016/S2468-1253(16)30205-9">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d95755e4843 class=n-a></a>Bellentani S, Saccoccio G, Costa G, <i> et al.</i>: Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. <i>Gut.</i> 1997; <b>41</b>(6): 845–50. <a target=xrefwindow id=d95755e4854 href="http://www.ncbi.nlm.nih.gov/pubmed/9462221">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4857 href="https://doi.org/10.1136/gut.41.6.845">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4861 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1891602">Free Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d95755e4870 class=n-a></a>Stickel F, Datz C, Hampe J, <i> et al.</i>: Pathophysiology and Management of Alcoholic Liver Disease: Update 2016. <i>Gut Liver.</i> 2017; <b>11</b>(2): 173–88. <a target=xrefwindow id=d95755e4881 href="http://www.ncbi.nlm.nih.gov/pubmed/28274107">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4884 href="https://doi.org/10.5009/gnl16477">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4888 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5347641">Free Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d95755e4897 class=n-a></a>Nanji AA, Su GL, Laposata M, <i> et al.</i>: Pathogenesis of alcoholic liver disease--recent advances. <i>Alcohol Clin Exp Res.</i> 2002; <b>26</b>(5): 731–6. <a target=xrefwindow id=d95755e4908 href="http://www.ncbi.nlm.nih.gov/pubmed/12045483">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4911 href="https://doi.org/10.1111/j.1530-0277.2002.tb02598.x">Publisher Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d95755e4920 class=n-a></a>Fukui H, Brauner B, Bode JC, <i> et al.</i>: Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. <i>J Hepatol.</i> 1991; <b>12</b>(2): 162–9. <a target=xrefwindow id=d95755e4931 href="http://www.ncbi.nlm.nih.gov/pubmed/2050995">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4934 href="https://doi.org/10.1016/0168-8278(91)90933-3">Publisher Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d95755e4944 class=n-a></a>Mandrekar P, Szabo G: Signalling pathways in alcohol-induced liver inflammation. <i>J Hepatol.</i> 2009; <b>50</b>(6): 1258–66. <a target=xrefwindow id=d95755e4952 href="http://www.ncbi.nlm.nih.gov/pubmed/19398236">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4955 href="https://doi.org/10.1016/j.jhep.2009.03.007">Publisher Full Text </a> | <a target=xrefwindow id=d95755e4958 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3342816">Free Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d95755e4967 class=n-a></a>Tilg H, Cani PD, Mayer EA: Gut microbiome and liver diseases. <i>Gut.</i> 2016; <b>65</b>(12): 2035–44. <a target=xrefwindow id=d95755e4975 href="http://www.ncbi.nlm.nih.gov/pubmed/27802157">PubMed Abstract </a> | <a target=xrefwindow id=d95755e4978 href="https://doi.org/10.1136/gutjnl-2016-312729">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d95755e4987 class=n-a></a>Verbeke KA, Boobis AR, Chiodini A, <i> et al.</i>: Towards microbial fermentation metabolites as markers for health benefits of prebiotics. <i>Nutr Res Rev.</i> 2015; <b>28</b>(1): 42–66. <a target=xrefwindow id=d95755e4998 href="http://www.ncbi.nlm.nih.gov/pubmed/26156216">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5001 href="https://doi.org/10.1017/S0954422415000037">Publisher Full Text </a> | <a target=xrefwindow id=d95755e5005 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4501371">Free Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a name=d95755e5014 class=n-a></a>Trivedi PJ, Adams DH: Mucosal immunity in liver autoimmunity: a comprehensive review. <i>J Autoimmun.</i> 2013; <b>46</b>: 97–111. <a target=xrefwindow id=d95755e5022 href="http://www.ncbi.nlm.nih.gov/pubmed/23891169">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5025 href="https://doi.org/10.1016/j.jaut.2013.06.013">Publisher Full Text </a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730126536"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e5034 class=n-a></a>Cohen LJ, Esterhazy D, Kim S, <i> et al.</i>: Commensal bacteria make GPCR ligands that mimic human signalling molecules. <i>Nature.</i> 2017; <b>549</b>(7670): 48–53. <a target=xrefwindow id=d95755e5045 href="http://www.ncbi.nlm.nih.gov/pubmed/28854168">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5048 href="https://doi.org/10.1038/nature23874">Publisher Full Text </a> | <a target=xrefwindow id=d95755e5052 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5777231">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730126536">F1000 Recommendation</a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d95755e5065 class=n-a></a>Bajaj JS, Betrapally NS, Hylemon PB, <i> et al.</i>: Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. <i>Hepatology.</i> 2015; <b>62</b>(4): 1260–71. <a target=xrefwindow id=d95755e5076 href="http://www.ncbi.nlm.nih.gov/pubmed/25820757">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5079 href="https://doi.org/10.1002/hep.27819">Publisher Full Text </a> | <a target=xrefwindow id=d95755e5083 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4587995">Free Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d95755e5093 class=n-a></a>Qin N, Yang F, Li A, <i> et al.</i>: Alterations of the human gut microbiome in liver cirrhosis. <i>Nature.</i> 2014; <b>513</b>(7516): 59–64. <a target=xrefwindow id=d95755e5104 href="http://www.ncbi.nlm.nih.gov/pubmed/25079328">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5107 href="https://doi.org/10.1038/nature13568">Publisher Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d95755e5116 class=n-a></a>Donnadieu-Rigole H, Pansu N, Mura T, <i> et al.</i>: Beneficial Effect of Alcohol Withdrawal on Gut Permeability and Microbial Translocation in Patients with Alcohol Use Disorder. <i>Alcohol Clin Exp Res.</i> 2018; <b>42</b>(1): 32–40. <a target=xrefwindow id=d95755e5127 href="http://www.ncbi.nlm.nih.gov/pubmed/29030980">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5130 href="https://doi.org/10.1111/acer.13527">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d95755e5139 class=n-a></a>Parlesak A, Schäfer C, Schütz T, <i> et al.</i>: Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. <i>J Hepatol.</i> 2000; <b>32</b>(5): 742–7. <a target=xrefwindow id=d95755e5150 href="http://www.ncbi.nlm.nih.gov/pubmed/10845660">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5153 href="https://doi.org/10.1016/S0168-8278(00)80242-1">Publisher Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d95755e5162 class=n-a></a>Bluemel S, Williams B, Knight R, <i> et al.</i>: Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. <i>Am J Physiol Gastrointest Liver Physiol.</i> 2016; <b>311</b>(6): G1018–G1036. <a target=xrefwindow id=d95755e5173 href="http://www.ncbi.nlm.nih.gov/pubmed/27686615">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5176 href="https://doi.org/10.1152/ajpgi.00245.2016">Publisher Full Text </a> | <a target=xrefwindow id=d95755e5180 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5206291">Free Full Text </a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d95755e5189 class=n-a></a>Arab JP, Martin-Mateos RM, Shah VH: Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. <i>Hepatol Int.</i> 2018; <b>12</b>(Suppl 1): 24–33. <a target=xrefwindow id=d95755e5197 href="http://www.ncbi.nlm.nih.gov/pubmed/28550391">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5200 href="https://doi.org/10.1007/s12072-017-9798-x">Publisher Full Text </a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a name=d95755e5209 class=n-a></a>Yang AM, Inamine T, Hochrath K, <i> et al.</i>: Intestinal fungi contribute to development of alcoholic liver disease. <i>J Clin Invest.</i> 2017; <b>127</b>(7): 2829–41. <a target=xrefwindow id=d95755e5220 href="http://www.ncbi.nlm.nih.gov/pubmed/28530644">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5223 href="https://doi.org/10.1172/JCI90562">Publisher Full Text </a> | <a target=xrefwindow id=d95755e5227 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5490775">Free Full Text </a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a name=d95755e5237 class=n-a></a>Beuers U, Trauner M, Jansen P, <i> et al.</i>: New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. <i>J Hepatol.</i> 2015; <b>62</b>(1 Suppl): S25–37. <a target=xrefwindow id=d95755e5248 href="http://www.ncbi.nlm.nih.gov/pubmed/25920087">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5251 href="https://doi.org/10.1016/j.jhep.2015.02.023">Publisher Full Text </a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a name=d95755e5260 class=n-a></a>Fickert P, Wagner M: Biliary bile acids in hepatobiliary injury - What is the link? <i>J Hepatol.</i> 2017; <b>67</b>(3): 619–31. <a target=xrefwindow id=d95755e5268 href="http://www.ncbi.nlm.nih.gov/pubmed/28712691">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5271 href="https://doi.org/10.1016/j.jhep.2017.04.026">Publisher Full Text </a></span></li><li><a name=ref-164 class=n-a></a><span class=label>164. </span>&nbsp;<span class=citation><a name=d95755e5280 class=n-a></a>Wiest R, Albillos A, Trauner M, <i> et al.</i>: Targeting the gut-liver axis in liver disease. <i>J Hepatol.</i> 2017; <b>67</b>(5): 1084–103. <a target=xrefwindow id=d95755e5291 href="http://www.ncbi.nlm.nih.gov/pubmed/28526488">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5294 href="https://doi.org/10.1016/j.jhep.2017.05.007">Publisher Full Text </a></span></li><li><a name=ref-165 class=n-a></a><span class=label>165. </span>&nbsp;<span class=citation><a name=d95755e5303 class=n-a></a>Woodhouse CA, Patel VC, Singanayagam A, <i> et al.</i>: Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. <i>Aliment Pharmacol Ther.</i> 2018; <b>47</b>(2): 192–202. <a target=xrefwindow id=d95755e5314 href="http://www.ncbi.nlm.nih.gov/pubmed/29083037">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5317 href="https://doi.org/10.1111/apt.14397">Publisher Full Text </a></span></li><li><a name=ref-166 class=n-a></a><span class=label>166. </span>&nbsp;<span class=citation><a name=d95755e5326 class=n-a></a>Fukui H: Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. <i>J Clin Transl Hepatol.</i> 2017; <b>5</b>(3): 249–60. <a target=xrefwindow id=d95755e5334 href="http://www.ncbi.nlm.nih.gov/pubmed/28936406">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5337 href="https://doi.org/10.14218/JCTH.2017.00008">Publisher Full Text </a> | <a target=xrefwindow id=d95755e5340 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5606971">Free Full Text </a></span></li><li><a name=ref-167 class=n-a></a><span class=label>167. </span>&nbsp;<span class=citation><a name=d95755e5349 class=n-a></a>Chen Y, Yang F, Lu H, <i> et al.</i>: Characterization of fecal microbial communities in patients with liver cirrhosis. <i>Hepatology.</i> 2011; <b>54</b>(2): 562–72. <a target=xrefwindow id=d95755e5360 href="http://www.ncbi.nlm.nih.gov/pubmed/21574172">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5363 href="https://doi.org/10.1002/hep.24423">Publisher Full Text </a></span></li><li><a name=ref-168 class=n-a></a><span class=label>168. </span>&nbsp;<span class=citation><a name=d95755e5373 class=n-a></a>Bajaj JS, Heuman DM, Hylemon PB, <i> et al.</i>: Altered profile of human gut microbiome is associated with cirrhosis and its complications. <i>J Hepatol.</i> 2014; <b>60</b>(5): 940–7. <a target=xrefwindow id=d95755e5384 href="http://www.ncbi.nlm.nih.gov/pubmed/24374295">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5387 href="https://doi.org/10.1016/j.jhep.2013.12.019">Publisher Full Text </a> | <a target=xrefwindow id=d95755e5391 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3995845">Free Full Text </a></span></li><li><a name=ref-169 class=n-a></a><span class=label>169. </span>&nbsp;<span class=citation><a name=d95755e5400 class=n-a></a>Dhiman RK, Rana B, Agrawal S, <i> et al.</i>: Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. <i>Gastroenterology.</i> 2014; <b>147</b>(6): 1327–37.e3. <a target=xrefwindow id=d95755e5411 href="http://www.ncbi.nlm.nih.gov/pubmed/25450083">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5414 href="https://doi.org/10.1053/j.gastro.2014.08.031">Publisher Full Text </a></span></li><li><a name=ref-170 class=n-a></a><span class=label>170. </span>&nbsp;<span class=citation><a name=d95755e5423 class=n-a></a>Gupta N, Kumar A, Sharma P, <i> et al.</i>: Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. <i>Liver Int.</i> 2013; <b>33</b>(8): 1148–57. <a target=xrefwindow id=d95755e5434 href="http://www.ncbi.nlm.nih.gov/pubmed/23601333">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5437 href="https://doi.org/10.1111/liv.12172">Publisher Full Text </a></span></li><li><a name=ref-171 class=n-a></a><span class=label>171. </span>&nbsp;<span class=citation><a name=d95755e5446 class=n-a></a>Bernard B, Grangé JD, Khac EN, <i> et al.</i>: Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. <i>Hepatology.</i> 1999; <b>29</b>(6): 1655–61. <a target=xrefwindow id=d95755e5457 href="http://www.ncbi.nlm.nih.gov/pubmed/10347104">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5460 href="https://doi.org/10.1002/hep.510290608">Publisher Full Text </a></span></li><li><a name=ref-172 class=n-a></a><span class=label>172. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1091957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e5469 class=n-a></a>Fernández J, Navasa M, Planas R, <i> et al.</i>: Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. <i>Gastroenterology.</i> 2007; <b>133</b>(3): 818–24. <a target=xrefwindow id=d95755e5480 href="http://www.ncbi.nlm.nih.gov/pubmed/17854593">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5483 href="https://doi.org/10.1053/j.gastro.2007.06.065">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1091957">F1000 Recommendation</a></span></li><li><a name=ref-173 class=n-a></a><span class=label>173. </span>&nbsp;<span class=citation><a name=d95755e5496 class=n-a></a>Moreau R, Elkrief L, Bureau C, <i> et al.</i>: A randomized trial of 6-month norfloxacin therapy in patients with Child-Pugh class C cirrhosis. <i>J Hepatol.</i> 2017; <b>66</b>(1): S1. <a target=xrefwindow id=d95755e5507 href="https://doi.org/10.1016/S0168-8278(17)30264-7">Publisher Full Text </a></span></li><li><a name=ref-174 class=n-a></a><span class=label>174. </span>&nbsp;<span class=citation><a name=d95755e5517 class=n-a></a>Rasaratnam B, Kaye D, Jennings G, <i> et al.</i>: The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. <i>Ann Intern Med.</i> 2003; <b>139</b>(3): 186–93. <a target=xrefwindow id=d95755e5528 href="http://www.ncbi.nlm.nih.gov/pubmed/12899586">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5531 href="https://doi.org/10.7326/0003-4819-139-3-200308050-00008">Publisher Full Text </a></span></li><li><a name=ref-175 class=n-a></a><span class=label>175. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2780957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e5540 class=n-a></a>Bass NM, Mullen KD, Sanyal A, <i> et al.</i>: Rifaximin treatment in hepatic encephalopathy. <i>N Engl J Med.</i> 2010; <b>362</b>(12): 1071–81. <a target=xrefwindow id=d95755e5551 href="http://www.ncbi.nlm.nih.gov/pubmed/20335583">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5554 href="https://doi.org/10.1056/NEJMoa0907893">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2780957">F1000 Recommendation</a></span></li><li><a name=ref-176 class=n-a></a><span class=label>176. </span>&nbsp;<span class=citation><a name=d95755e5567 class=n-a></a>Bajaj JS: Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. <i>Aliment Pharmacol Ther.</i> 2016; <b>43 Suppl 1</b>: 11–26. <a target=xrefwindow id=d95755e5575 href="http://www.ncbi.nlm.nih.gov/pubmed/26618922">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5578 href="https://doi.org/10.1111/apt.13435">Publisher Full Text </a></span></li><li><a name=ref-177 class=n-a></a><span class=label>177. </span>&nbsp;<span class=citation><a name=d95755e5587 class=n-a></a>Ponziani FR, Zocco MA, D'Aversa F, <i> et al.</i>: Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. <i>World J Gastroenterol.</i> 2017; <b>23</b>(25): 4491–9. <a target=xrefwindow id=d95755e5598 href="http://www.ncbi.nlm.nih.gov/pubmed/28740337">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5601 href="https://doi.org/10.3748/wjg.v23.i25.4491">Publisher Full Text </a> | <a target=xrefwindow id=d95755e5605 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5504364">Free Full Text </a></span></li><li><a name=ref-178 class=n-a></a><span class=label>178. </span>&nbsp;<span class=citation><a name=d95755e5614 class=n-a></a>Vlachogiannakos J, Saveriadis AS, Viazis N, <i> et al.</i>: Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. <i>Aliment Pharmacol Ther.</i> 2009; <b>29</b>(9): 992–9. <a target=xrefwindow id=d95755e5625 href="http://www.ncbi.nlm.nih.gov/pubmed/19210289">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5628 href="https://doi.org/10.1111/j.1365-2036.2009.03958.x">Publisher Full Text </a></span></li><li><a name=ref-179 class=n-a></a><span class=label>179. </span>&nbsp;<span class=citation><a name=d95755e5637 class=n-a></a>Vlachogiannakos J, Viazis N, Vasianopoulou P, <i> et al.</i>: Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. <i>J Gastroenterol Hepatol.</i> 2013; <b>28</b>(3): 450–5. <a target=xrefwindow id=d95755e5648 href="http://www.ncbi.nlm.nih.gov/pubmed/23216382">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5651 href="https://doi.org/10.1111/jgh.12070">Publisher Full Text </a></span></li><li><a name=ref-180 class=n-a></a><span class=label>180. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726880878"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e5661 class=n-a></a>Kimer N, Pedersen JS, Busk TM, <i> et al.</i>: Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. <i>Hepatology.</i> 2017; <b>65</b>(2): 592–603. <a target=xrefwindow id=d95755e5672 href="http://www.ncbi.nlm.nih.gov/pubmed/27775818">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5675 href="https://doi.org/10.1002/hep.28898">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726880878">F1000 Recommendation</a></span></li><li><a name=ref-181 class=n-a></a><span class=label>181. </span>&nbsp;<span class=citation><a name=d95755e5688 class=n-a></a>Kimer N, Pedersen JS, Tavenier J, <i> et al.</i>: Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. <i>J Gastroenterol Hepatol.</i> 2018; <b>33</b>(1): 307–14. <a target=xrefwindow id=d95755e5699 href="http://www.ncbi.nlm.nih.gov/pubmed/28671712">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5702 href="https://doi.org/10.1111/jgh.13852">Publisher Full Text </a></span></li><li><a name=ref-182 class=n-a></a><span class=label>182. </span>&nbsp;<span class=citation><a name=d95755e5711 class=n-a></a>Paumgartner G: Pharmacotherapy of cholestatic liver diseases. <i>J Dig Dis.</i> 2010; <b>11</b>(3): 119–25. <a target=xrefwindow id=d95755e5719 href="http://www.ncbi.nlm.nih.gov/pubmed/20579215">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5722 href="https://doi.org/10.1111/j.1751-2980.2010.00427.x">Publisher Full Text </a></span></li><li><a name=ref-183 class=n-a></a><span class=label>183. </span>&nbsp;<span class=citation><a name=d95755e5731 class=n-a></a>Trauner M, Fuchs CD, Halilbasic E, <i> et al.</i>: New therapeutic concepts in bile acid transport and signaling for management of cholestasis. <i>Hepatology.</i> 2017; <b>65</b>(4): 1393–404. <a target=xrefwindow id=d95755e5742 href="http://www.ncbi.nlm.nih.gov/pubmed/27997980">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5745 href="https://doi.org/10.1002/hep.28991">Publisher Full Text </a></span></li><li><a name=ref-184 class=n-a></a><span class=label>184. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726749157"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e5754 class=n-a></a>Gonzalez FJ, Jiang C, Patterson AD: An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. <i>Gastroenterology.</i> 2016; <b>151</b>(5): 845–59. <a target=xrefwindow id=d95755e5762 href="http://www.ncbi.nlm.nih.gov/pubmed/27639801">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5765 href="https://doi.org/10.1053/j.gastro.2016.08.057">Publisher Full Text </a> | <a target=xrefwindow id=d95755e5768 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5159222">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726749157">F1000 Recommendation</a></span></li><li><a name=ref-185 class=n-a></a><span class=label>185. </span>&nbsp;<span class=citation><a name=d95755e5781 class=n-a></a>Chávez-Talavera O, Tailleux A, Lefebvre P, <i> et al.</i>: Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology.</i> 2017; <b>152</b>(7): 1679–1694.e3. <a target=xrefwindow id=d95755e5792 href="http://www.ncbi.nlm.nih.gov/pubmed/28214524">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5795 href="https://doi.org/10.1053/j.gastro.2017.01.055">Publisher Full Text </a></span></li><li><a name=ref-186 class=n-a></a><span class=label>186. </span>&nbsp;<span class=citation><a name=d95755e5805 class=n-a></a>Schubert K, Olde Damink SWM, von Bergen M, <i> et al.</i>: Interactions between bile salts, gut microbiota, and hepatic innate immunity. <i>Immunol Rev.</i> 2017; <b>279</b>(1): 23–35. <a target=xrefwindow id=d95755e5816 href="http://www.ncbi.nlm.nih.gov/pubmed/28856736">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5819 href="https://doi.org/10.1111/imr.12579">Publisher Full Text </a></span></li><li><a name=ref-187 class=n-a></a><span class=label>187. </span>&nbsp;<span class=citation><a name=d95755e5828 class=n-a></a>Verbeke L, Farre R, Trebicka J, <i> et al.</i>: Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. <i>Hepatology.</i> 2014; <b>59</b>(6): 2286–98. <a target=xrefwindow id=d95755e5839 href="http://www.ncbi.nlm.nih.gov/pubmed/24259407">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5842 href="https://doi.org/10.1002/hep.26939">Publisher Full Text </a></span></li><li><a name=ref-188 class=n-a></a><span class=label>188. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727127707"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e5851 class=n-a></a>Schwabl P, Hambruch E, Seeland BA, <i> et al.</i>: The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. <i>J Hepato.</i> 2017; <b>66</b>(4): 724–33. <a target=xrefwindow id=d95755e5862 href="http://www.ncbi.nlm.nih.gov/pubmed/27993716">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5865 href="https://doi.org/10.1016/j.jhep.2016.12.005">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727127707">F1000 Recommendation</a></span></li><li><a name=ref-189 class=n-a></a><span class=label>189. </span>&nbsp;<span class=citation><a name=d95755e5878 class=n-a></a>Nevens F, Andreone P, Mazzella G, <i> et al.</i>: A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>N Engl J Med.</i> 2016; <b>375</b>(7): 631–43. <a target=xrefwindow id=d95755e5889 href="http://www.ncbi.nlm.nih.gov/pubmed/27532829">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5892 href="https://doi.org/10.1056/NEJMoa1509840">Publisher Full Text </a></span></li><li><a name=ref-190 class=n-a></a><span class=label>190. </span>&nbsp;<span class=citation><a name=d95755e5901 class=n-a></a>Carino A, Cipriani S, Marchianò S, <i> et al.</i>: BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. <i>Sci Rep.</i> 2017; <b>7</b>: 42801. <a target=xrefwindow id=d95755e5912 href="http://www.ncbi.nlm.nih.gov/pubmed/28202906">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5915 href="https://doi.org/10.1038/srep42801">Publisher Full Text </a> | <a target=xrefwindow id=d95755e5919 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5311892">Free Full Text </a></span></li><li><a name=ref-191 class=n-a></a><span class=label>191. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727689876"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e5928 class=n-a></a>Bajaj JS, Kassam Z, Fagan A, <i> et al.</i>: Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. <i>Hepatology.</i> 2017; <b>66</b>(6): 1727–38. <a target=xrefwindow id=d95755e5939 href="http://www.ncbi.nlm.nih.gov/pubmed/28586116">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5942 href="https://doi.org/10.1002/hep.29306">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727689876">F1000 Recommendation</a></span></li><li><a name=ref-192 class=n-a></a><span class=label>192. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726446677"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e5956 class=n-a></a>Kang DJ, Betrapally NS, Ghosh SA, <i> et al.</i>: Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. <i>Hepatology.</i> 2016; <b>64</b>(4): 1232–48. <a target=xrefwindow id=d95755e5967 href="http://www.ncbi.nlm.nih.gov/pubmed/27339732">PubMed Abstract </a> | <a target=xrefwindow id=d95755e5970 href="https://doi.org/10.1002/hep.28696">Publisher Full Text </a> | <a target=xrefwindow id=d95755e5974 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5033692">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726446677">F1000 Recommendation</a></span></li><li><a name=ref-193 class=n-a></a><span class=label>193. </span>&nbsp;<span class=citation><a name=d95755e5987 class=n-a></a>Milanski M, Arruda AP, Coope A, <i> et al.</i>: Inhibition of hypothalamic inflammation reverses diet-induced insulin resistance in the liver. <i>Diabetes.</i> 2012; <b>61</b>(6): 1455–62. <a target=xrefwindow id=d95755e5998 href="http://www.ncbi.nlm.nih.gov/pubmed/22522614">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6001 href="https://doi.org/10.2337/db11-0390">Publisher Full Text </a> | <a target=xrefwindow id=d95755e6005 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3357298">Free Full Text </a></span></li><li><a name=ref-194 class=n-a></a><span class=label>194. </span>&nbsp;<span class=citation><a name=d95755e6014 class=n-a></a>Waise TMZ, Toshinai K, Naznin F, <i> et al.</i>: One-day high-fat diet induces inflammation in the nodose ganglion and hypothalamus of mice. <i>Biochem Biophys Res Commun.</i> 2015; <b>464</b>(4): 1157–62. <a target=xrefwindow id=d95755e6025 href="http://www.ncbi.nlm.nih.gov/pubmed/26208455">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6028 href="https://doi.org/10.1016/j.bbrc.2015.07.097">Publisher Full Text </a></span></li><li><a name=ref-195 class=n-a></a><span class=label>195. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13477013"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e6037 class=n-a></a>Thaler JP, Yi C, Schur EA, <i> et al.</i>: Obesity is associated with hypothalamic injury in rodents and humans. <i>J Clin Invest.</i> 2012; <b>122</b>(1): 153–62. <a target=xrefwindow id=d95755e6048 href="http://www.ncbi.nlm.nih.gov/pubmed/22201683">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6051 href="https://doi.org/10.1172/JCI59660">Publisher Full Text </a> | <a target=xrefwindow id=d95755e6055 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3248304">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13477013">F1000 Recommendation</a></span></li><li><a name=ref-196 class=n-a></a><span class=label>196. </span>&nbsp;<span class=citation><a name=d95755e6068 class=n-a></a>Gardemann A, Püschel GP, Jungermann K: Nervous control of liver metabolism and hemodynamics. <i>Eur J Biochem.</i> 1992; <b>207</b>(2): 399–411. <a target=xrefwindow id=d95755e6076 href="http://www.ncbi.nlm.nih.gov/pubmed/1633798">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6079 href="https://doi.org/10.1111/j.1432-1033.1992.tb17063.x">Publisher Full Text </a></span></li><li><a name=ref-197 class=n-a></a><span class=label>197. </span>&nbsp;<span class=citation><a name=d95755e6088 class=n-a></a>Leclercq S, de Timary P, Delzenne NM: The link between inflammation, bugs, the intestine and the brain in alcohol dependence. <i>Transl Psychiatry.</i> 2017; <b>7</b>(2): e1048. <a target=xrefwindow id=d95755e6096 href="http://www.ncbi.nlm.nih.gov/pubmed/28244981">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6099 href="https://doi.org/10.1038/tp.2017.15">Publisher Full Text </a> | <a target=xrefwindow id=d95755e6102 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5545644">Free Full Text </a></span></li><li><a name=ref-198 class=n-a></a><span class=label>198. </span>&nbsp;<span class=citation><a name=d95755e6112 class=n-a></a>Temko JE, Bouhlal S, Farokhnia M, <i> et al.</i>: The Microbiota, the Gut and the Brain in Eating and Alcohol Use Disorders: A 'Ménage à Trois'? <i>Alcohol Alcohol.</i> 2017; <b>52</b>(4): 403–13. <a target=xrefwindow id=d95755e6123 href="http://www.ncbi.nlm.nih.gov/pubmed/28482009">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6126 href="https://doi.org/10.1093/alcalc/agx024">Publisher Full Text </a> | <a target=xrefwindow id=d95755e6130 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5860274">Free Full Text </a></span></li><li><a name=ref-199 class=n-a></a><span class=label>199. </span>&nbsp;<span class=citation><a name=d95755e6139 class=n-a></a>Velloso LA, Folli F, Saad MJ: TLR4 at the Crossroads of Nutrients, Gut Microbiota, and Metabolic Inflammation. <i>Endocr Rev.</i> 2015; <b>36</b>(3): 245–71. <a target=xrefwindow id=d95755e6147 href="http://www.ncbi.nlm.nih.gov/pubmed/25811237">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6150 href="https://doi.org/10.1210/er.2014-1100">Publisher Full Text </a></span></li><li><a name=ref-200 class=n-a></a><span class=label>200. </span>&nbsp;<span class=citation><a name=d95755e6159 class=n-a></a>Berzigotti A, Albillos A, Villanueva C, <i> et al.</i>: Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. <i>Hepatology.</i> 2017; <b>65</b>(4): 1293–305. <a target=xrefwindow id=d95755e6170 href="http://www.ncbi.nlm.nih.gov/pubmed/27997989">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6173 href="https://doi.org/10.1002/hep.28992">Publisher Full Text </a></span></li><li><a name=ref-201 class=n-a></a><span class=label>201. </span>&nbsp;<span class=citation><a name=d95755e6182 class=n-a></a>Müting D, Kalk JF, Fischer R, <i> et al.</i>: Spontaneous regression of oesophageal varices after long-term conservative treatment. Retrospective study in 20 patients with alcoholic liver cirrhosis, posthepatitic cirrhosis and haemochromatosis with cirrhosis. <i>J Hepatol.</i> 1990; <b>10</b>(2): 158–62. <a target=xrefwindow id=d95755e6193 href="http://www.ncbi.nlm.nih.gov/pubmed/2332585">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6196 href="https://doi.org/10.1016/0168-8278(90)90045-S">Publisher Full Text </a></span></li><li><a name=ref-202 class=n-a></a><span class=label>202. </span>&nbsp;<span class=citation><a name=d95755e6205 class=n-a></a>Francoz C, Valla D, Durand F: Portal vein thrombosis, cirrhosis, and liver transplantation. <i>J Hepatol.</i> 2012; <b>57</b>(1): 203–12. <a target=xrefwindow id=d95755e6213 href="http://www.ncbi.nlm.nih.gov/pubmed/22446690">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6216 href="https://doi.org/10.1016/j.jhep.2011.12.034">Publisher Full Text </a></span></li><li><a name=ref-203 class=n-a></a><span class=label>203. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717953176"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e6225 class=n-a></a>Villa E, Cammà C, Marietta M, <i> et al.</i>: Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. <i>Gastroenterology.</i> 2012; <b>143</b>(5): 1253–60.e1-4. <a target=xrefwindow id=d95755e6236 href="http://www.ncbi.nlm.nih.gov/pubmed/22819864">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6239 href="https://doi.org/10.1053/j.gastro.2012.07.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717953176">F1000 Recommendation</a></span></li><li><a name=ref-204 class=n-a></a><span class=label>204. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727592802"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e6253 class=n-a></a>Loffredo L, Pastori D, Farcomeni A, <i> et al.</i>: Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. <i>Gastroenterology.</i> 2017; <b>153</b>(2): 480–487.e1. <a target=xrefwindow id=d95755e6264 href="http://www.ncbi.nlm.nih.gov/pubmed/28479379">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6267 href="https://doi.org/10.1053/j.gastro.2017.04.042">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727592802">F1000 Recommendation</a></span></li><li><a name=ref-205 class=n-a></a><span class=label>205. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726028173"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d95755e6280 class=n-a></a>Cerini F, Vilaseca M, Lafoz E, <i> et al.</i>: Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. <i>J Hepatol.</i> 2016; <b>64</b>(4): 834–42. <a target=xrefwindow id=d95755e6291 href="http://www.ncbi.nlm.nih.gov/pubmed/26686269">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6294 href="https://doi.org/10.1016/j.jhep.2015.12.003">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726028173">F1000 Recommendation</a></span></li><li><a name=ref-206 class=n-a></a><span class=label>206. </span>&nbsp;<span class=citation><a name=d95755e6307 class=n-a></a>Schwabl P, Laleman W: Novel treatment options for portal hypertension. <i>Gastroenterol Rep (Oxf).</i> 2017; <b>5</b>(2): 90–103. <a target=xrefwindow id=d95755e6315 href="http://www.ncbi.nlm.nih.gov/pubmed/28533907">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6318 href="https://doi.org/10.1093/gastro/gox011">Publisher Full Text </a> | <a target=xrefwindow id=d95755e6321 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5421460">Free Full Text </a></span></li><li><a name=ref-207 class=n-a></a><span class=label>207. </span>&nbsp;<span class=citation><a name=d95755e6330 class=n-a></a>Heller J, Shiozawa T, Trebicka J, <i> et al.</i>: Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. <i>Eur J Clin Invest.</i> 2003; <b>33</b>(11): 1006–12. <a target=xrefwindow id=d95755e6341 href="http://www.ncbi.nlm.nih.gov/pubmed/14636305">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6344 href="https://doi.org/10.1046/j.1365-2362.2003.01251.x">Publisher Full Text </a></span></li><li><a name=ref-208 class=n-a></a><span class=label>208. </span>&nbsp;<span class=citation><a name=d95755e6353 class=n-a></a>Hennenberg M, Biecker E, Trebicka J, <i> et al.</i>: Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. <i>Gastroenterology.</i> 2006; <b>130</b>(3): 838–54. <a target=xrefwindow id=d95755e6364 href="http://www.ncbi.nlm.nih.gov/pubmed/16530523">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6367 href="https://doi.org/10.1053/j.gastro.2005.11.029">Publisher Full Text </a></span></li><li><a name=ref-209 class=n-a></a><span class=label>209. </span>&nbsp;<span class=citation><a name=d95755e6376 class=n-a></a>Hennenberg M, Trebicka J, Kohistani Z, <i> et al.</i>: Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. <i>Lab Invest.</i> 2011; <b>91</b>(2): 241–51. <a target=xrefwindow id=d95755e6387 href="http://www.ncbi.nlm.nih.gov/pubmed/20921950">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6390 href="https://doi.org/10.1038/labinvest.2010.148">Publisher Full Text </a></span></li><li><a name=ref-210 class=n-a></a><span class=label>210. </span>&nbsp;<span class=citation><a name=d95755e6400 class=n-a></a>Berzigotti A, Bellot P, De Gottardi A, <i> et al.</i>: NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. <i>Am J Gastroenterol.</i> 2010; <b>105</b>(5): 1094–101. <a target=xrefwindow id=d95755e6411 href="http://www.ncbi.nlm.nih.gov/pubmed/19920806">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6414 href="https://doi.org/10.1038/ajg.2009.661">Publisher Full Text </a></span></li><li><a name=ref-211 class=n-a></a><span class=label>211. </span>&nbsp;<span class=citation><a name=d95755e6423 class=n-a></a>Biecker E, Trebicka J, Kang A, <i> et al.</i>: Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. <i>Liver Int.</i> 2008; <b>28</b>(3): 331–8. <a target=xrefwindow id=d95755e6434 href="http://www.ncbi.nlm.nih.gov/pubmed/18290775">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6437 href="https://doi.org/10.1111/j.1478-3231.2008.01664.x">Publisher Full Text </a></span></li><li><a name=ref-212 class=n-a></a><span class=label>212. </span>&nbsp;<span class=citation><a name=d95755e6446 class=n-a></a>Fiorucci S, Antonelli E, Morelli O, <i> et al.</i>: NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. <i>Proc Natl Acad Sci U S A.</i> 2001; <b>98</b>(15): 8897–902. <a target=xrefwindow id=d95755e6457 href="http://www.ncbi.nlm.nih.gov/pubmed/11447266">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6460 href="https://doi.org/10.1073/pnas.151136298">Publisher Full Text </a> | <a target=xrefwindow id=d95755e6464 href="http://www.ncbi.nlm.nih.gov/pmc/articles/37532">Free Full Text </a></span></li><li><a name=ref-213 class=n-a></a><span class=label>213. </span>&nbsp;<span class=citation><a name=d95755e6473 class=n-a></a>Fiorucci S, Antonelli E, Brancaleone V, <i> et al.</i>: NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. <i>J Hepatol.</i> 2003; <b>39</b>(6): 932–9. <a target=xrefwindow id=d95755e6484 href="http://www.ncbi.nlm.nih.gov/pubmed/14642608">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6487 href="https://doi.org/10.1016/S0168-8278(03)00393-3">Publisher Full Text </a></span></li><li><a name=ref-214 class=n-a></a><span class=label>214. </span>&nbsp;<span class=citation><a name=d95755e6496 class=n-a></a>Zhou Q, Hennenberg M, Trebicka J, <i> et al.</i>: Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. <i>Gut.</i> 2006; <b>55</b>(9): 1296–305. <a target=xrefwindow id=d95755e6507 href="http://www.ncbi.nlm.nih.gov/pubmed/16492715">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6510 href="https://doi.org/10.1136/gut.2005.081059">Publisher Full Text </a> | <a target=xrefwindow id=d95755e6514 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1860046">Free Full Text </a></span></li><li><a name=ref-215 class=n-a></a><span class=label>215. </span>&nbsp;<span class=citation><a name=d95755e6523 class=n-a></a>Grace JA, Klein S, Herath CB, <i> et al.</i>: Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. <i>Gastroenterology.</i> 2013; <b>145</b>(4): 874–884.e5. <a target=xrefwindow id=d95755e6534 href="http://www.ncbi.nlm.nih.gov/pubmed/23796456">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6537 href="https://doi.org/10.1053/j.gastro.2013.06.036">Publisher Full Text </a></span></li><li><a name=ref-216 class=n-a></a><span class=label>216. </span>&nbsp;<span class=citation><a name=d95755e6547 class=n-a></a>Granzow M, Schierwagen R, Klein S, <i> et al.</i>: Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. <i>Hepatology.</i> 2014; <b>60</b>(1): 334–48. <a target=xrefwindow id=d95755e6558 href="http://www.ncbi.nlm.nih.gov/pubmed/24619965">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6561 href="https://doi.org/10.1002/hep.27117">Publisher Full Text </a> | <a target=xrefwindow id=d95755e6565 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5512562">Free Full Text </a></span></li><li><a name=ref-217 class=n-a></a><span class=label>217. </span>&nbsp;<span class=citation><a name=d95755e6574 class=n-a></a>Heller J, Trebicka J, Shiozawa T, <i> et al.</i>: Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. <i>Liver Int.</i> 2005; <b>25</b>(3): 657–66. <a target=xrefwindow id=d95755e6585 href="http://www.ncbi.nlm.nih.gov/pubmed/15910503">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6588 href="https://doi.org/10.1111/j.1478-3231.2005.01053.x">Publisher Full Text </a></span></li><li><a name=ref-218 class=n-a></a><span class=label>218. </span>&nbsp;<span class=citation><a name=d95755e6597 class=n-a></a>Hennenberg M, Trebicka J, Stark C, <i> et al.</i>: Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. <i>Br J Pharmacol.</i> 2009; <b>157</b>(2): 258–70. <a target=xrefwindow id=d95755e6608 href="http://www.ncbi.nlm.nih.gov/pubmed/19338580">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6611 href="https://doi.org/10.1111/j.1476-5381.2009.00158.x">Publisher Full Text </a> | <a target=xrefwindow id=d95755e6615 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2697813">Free Full Text </a></span></li><li><a name=ref-219 class=n-a></a><span class=label>219. </span>&nbsp;<span class=citation><a name=d95755e6624 class=n-a></a>Klein S, Herath CB, Schierwagen R, <i> et al.</i>: Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. <i>PLoS One.</i> 2015; <b>10</b>(9): e0138732. <a target=xrefwindow id=d95755e6635 href="http://www.ncbi.nlm.nih.gov/pubmed/26406236">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6638 href="https://doi.org/10.1371/journal.pone.0138732">Publisher Full Text </a> | <a target=xrefwindow id=d95755e6642 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4583473">Free Full Text </a></span></li><li><a name=ref-220 class=n-a></a><span class=label>220. </span>&nbsp;<span class=citation><a name=d95755e6651 class=n-a></a>Klein S, Rick J, Lehmann J, <i> et al.</i>: Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. <i>Gut.</i> 2017; <b>66</b>(1): 145–55. <a target=xrefwindow id=d95755e6662 href="http://www.ncbi.nlm.nih.gov/pubmed/26385087">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6665 href="https://doi.org/10.1136/gutjnl-2015-309600">Publisher Full Text </a></span></li><li><a name=ref-221 class=n-a></a><span class=label>221. </span>&nbsp;<span class=citation><a name=d95755e6674 class=n-a></a>Kreisel W, Deibert P, Kupcinskas L, <i> et al.</i>: The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. <i>Dig Liver Dis.</i> 2015; <b>47</b>(2): 144–50. <a target=xrefwindow id=d95755e6685 href="http://www.ncbi.nlm.nih.gov/pubmed/25483910">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6688 href="https://doi.org/10.1016/j.dld.2014.10.018">Publisher Full Text </a></span></li><li><a name=ref-222 class=n-a></a><span class=label>222. </span>&nbsp;<span class=citation><a name=d95755e6698 class=n-a></a>Trebicka J, Leifeld L, Hennenberg M, <i> et al.</i>: Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. <i>Hepatology.</i> 2008; <b>47</b>(4): 1264–76. <a target=xrefwindow id=d95755e6709 href="http://www.ncbi.nlm.nih.gov/pubmed/18318439">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6712 href="https://doi.org/10.1002/hep.22170">Publisher Full Text </a></span></li><li><a name=ref-223 class=n-a></a><span class=label>223. </span>&nbsp;<span class=citation><a name=d95755e6721 class=n-a></a>Trebicka J, Hennenberg M, Schulze Pröbsting A, <i> et al.</i>: Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. <i>Hepatology.</i> 2009; <b>50</b>(6): 1924–35. <a target=xrefwindow id=d95755e6732 href="http://www.ncbi.nlm.nih.gov/pubmed/19842096">PubMed Abstract </a> | <a target=xrefwindow id=d95755e6735 href="https://doi.org/10.1002/hep.23222">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 02 May 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-533/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-533/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Internal Medicine, University of Bonn, Bonn, Germany<br/> <sup>2</sup> European Foundation for Study of Chronic Liver Failure, Barcelona, Spain<br/> <p> <div class=margin-bottom> Tilman Sauerbruch <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Robert Schierwagen <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Jonel Trebicka <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-533/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 02 May 2018, 7:533 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.13943.1">https://doi.org/10.12688/f1000research.13943.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Sauerbruch T <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=15157 data-id=13943 data-downloads="" data-views="" data-scholar="10.12688/f1000research.13943.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-533/v1/pdf?article_uuid=440d6d98-e9fa-45cc-b787-9b59b64fc85a" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.13943.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Sauerbruch T, Schierwagen R and Trebicka J. Managing portal hypertension in patients with liver cirrhosis [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):533 (<a href="https://doi.org/10.12688/f1000research.13943.1" target=_blank>https://doi.org/10.12688/f1000research.13943.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=13943 id=mobile-track-article-signin-13943 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/13943?target=/articles/7-533/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15157 /> <input name=articleId type=hidden value=13943 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Florence Wong</strong>, Division of Gastroenterology, Department of Medicine, Toronto General Hospital, Canada </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Vijay H. Shah</strong>, Division of Gastroenterology and Hepatology, Mayo Clinic, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 02 May 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-533/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-533/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=33967-33469></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=10304-33470></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-533/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>02 May 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Florence Wong</strong>, Division of Gastroenterology, Department of Medicine, Toronto General Hospital, Canada </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Vijay H. Shah</strong>, Division of Gastroenterology and Hepatology, Mayo Clinic, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-533/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-533/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Managing portal hypertension in patients...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-533/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-533/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-533/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Sauerbruch T et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-533/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-533",
            templates : {
                twitter : "Managing portal hypertension in patients with liver cirrhosis. Sauerbruch T et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-533/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Managing portal hypertension in patients with liver cirrhosis", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Managing portal hypertension in patients with liver cirrhosis", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/13943/15157")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "15157");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "33469": 0,
                           "33470": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "ac059ce3-0863-41ff-9cef-79ad9d7f90b5";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-533.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-533.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-533.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-533.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-533.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>